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ABSTRACT
Infections with dengue viruses (DENV) constitute both a global problem as well as locally
in Florida. DENV comprise four distinct serotypes of single-stranded RNA viruses and belong to
the family Flaviviridae. DENV are among the most medically important arboviruses in the world
and cases may currently exceed 400 million per annum. Additionally, dengue established its first
recorded endemic transmission cycle in the state of Florida in over a half century, first within the
Florida Keys during 2009-10 followed by an unrelated outbreak in Martin County in 2013. The
clinical profile of DENV infections ranges from a mild febrile illness to severe illness including
hemorrhaging and/or shock, occasionally leading to death. Asymptomatic and mild cases also
play a role in maintaining transmission cycles. The early diagnosis and management of patients
at the clinical level have both proven to be major obstacles in the control of DENV and are
important at both the individual and community levels. Individually, the proper management of
patients that will progress to severe illness demands that they are identified in order to receive
supportive treatment and mitigate associated morbidity and mortality. At the community level,
early diagnosis may reduce transmission by limiting the possibility of vector contact with viremic
individuals. Early diagnosis is dependent on the detection of viral markers, while a number of
host factors may inform prognosis. The microsphere-based immunoassay (MIA) is capable of
detecting up to 100 different targets in a single sample and therefore would be useful as a single
assay for determining both. This study attempted to develop a diagnostic and prognostic MIA
using the DENV NS1 glycoprotein and 5 host markers as targets. For the purposes of DENV
NS1 detection in MIA, a set of monoclonal antibodies (mAbs) were subjected to
immunoprecipitation and/or Western blot analysis in order to determine immunoreactivity. Two
mAbs, 3A5.4 and 3D1.4, were chosen for use in MIA as a capture antibody and a detection
antibody, respectively, and the results compared to a commercially available DENV NS1 ELISA.
The 5 markers chosen for MIA trials included GM-CSF, IFN-γ, IP-10, IL-10, and MCP-1 and were
selected from a panel of 27 markers screened initially in two in vitro models of DENV infection in

ix

addition to serum samples. The two cell lines investigated were HPMEC ST1.6R and u937 as
both are thought to play important roles in models of DENV pathogenesis. The results of the
DENV NS1 detection MIA were initially promising but were ultimately unsuccessful. When
measuring host markers in the MIA, results pointed towards certain profiles that may be of future
use. IL-10 was found to be elevated in a statistically significant manner in DENV qRT-PCR+
samples (p=0.035) when compared to negative sera. MCP-1 elevation was found to be of
borderline significance (p=0.058). Other potential markers based on the results reported here
include IP-10, IL-6, IL-8, VEGF, and RANTES. The ultimate goal of measuring host markers is to
gain the ability to differentiate patients that will progress to severe illness from those that will
recover. In conclusion, despite the failure of the MIA to detect DENV NS1 in human sera, our
results in determining host markers and developments leading to successful DENV NS1 detection
ELISAs elsewhere lead us to believe that this approach remains promising. Major drawbacks of
this study included the lack of samples from patients that experienced severe DENV illness as a
comparative group in addition to small sample sizes. Future goals should include determining the
reasons for the failure of the MIA in detecting DENV NS1, selecting a panel of appropriate
markers to differentiate non-severe from severe cases of DENV prior to progression, and
optimizing the inclusion of these markers to an appropriate number.
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CHAPTER 1. LITERATURE REVIEW, STATEMENT OF THE PROBLEM, AND SPECIFIC AIMS

1.1. Literature Review

1.1.1. Introduction - the Flaviviruses

The family Flaviviridae includes 3 genera: Flavivirus, Hepacivirus, and Pestivirus. Within the
flaviviruses, the literature mentions that there are now over seventy recognized members of the genus.
This is a somewhat reduced number from that historically recognized, as the family Flaviviridae has
recently been separated from the Togaviridae. (Petersen and Barrett, 2009) The formal separation
occurred after 1980 due to the work of Calisher and others (Calisher et al., 1989). This number is slowly
increasing due both to previously unrecognized viruses emerging in addition to divergent evolution of
extant species. It should be noted that as of 2014 the ICTV database lists 53 species (ICTV, 2014) while
in contrast there are 116 listed in the NCBI taxonomy database (with DENV1-4 as a single species)
(NCBI, 2014). Regardless, nearly all species within the genus Flavivirus are maintained in a transmission
cycle between arthropod and vertebrate hosts, while many are known to affect humans. The name
flavivirus itself is derived from that of the prototype virus of the family, the yellow fever virus (YFV).
Yellow fever has been recognized as a disease entity as far back as 1647-1648 when it first caused
epidemics in the New World (Marr, 2013; Staples and Monath, 2008) while dengue has been described
specifically since 1827 (Gibbons et al., 2012; Horlbeck, 1896; Thomas, 1880).
Flaviviruses encode a genome of approximately 10,000 nucleotides in the form of a positivesensed, single-stranded RNA. The genome is arranged in a 5’-3’ manner encoding 10 proteins (3
structural, 7 non-structural) in a single open-reading frame (ORF) and is capped on both ends by
functional non-coding regions. Genomic organization is the primary reason for their separation from
alphaviruses (Togaviridae), as flaviviruses lack a 3’ poly-A tail and as opposed to alphaviruses, their
structural proteins are located upstream (5’) with regards to the non-structural proteins. The 3 structural
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proteins of flaviviruses are located at the 5’ end of the ORF and include, in order, the capsid (C), premembrane/membrane (prM/M), and envelope (env or E) proteins. (Petersen and Barrett, 2009)
The envelope protein is considered to contain the dominant immunogenic epitope responsible for
generating what are thought to be the most effective neutralizing antibodies in humans. Further
downstream, the genome encodes 7 non-structural (NS) proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B,
and the viral RNA-dependent RNA polymerase, NS5. Historically, flaviviruses have been classified into
as many as 8 complexes according to antigenic responses within neutralization tests. (Petersen and
Barrett, 2009) Genetic analyses based upon arguably the most diversified viral protein (env) and the
most conserved (NS5) have placed flaviviruses in one of four phylogenetic clades: Culex, Aedes, Tickborne, and Rio Bravo. The Culex clade includes viruses that are primarily vectored by Culex spp.
mosquitoes and usually cause encephalitic disease in incidental or dead-end hosts, such as humans.
These viruses include West Nile virus (WNV), St. Louis encephalitis virus (SLEV), Kunjin virus, and
Japanese encephalitis virus (JEV). The Aedes clade viruses are most often transmitted by Aedes spp.
mosquitoes, have the capacity to cause hemorrhagic fever in humans, and contains the prototypical
flavivirus, yellow fever virus (YFV). This clade additionally counts dengue virus (DENV) serotypes 1-4
and Zika virus (ZIKV) among its members. The third clade contains those flaviviruses vectored by ticks
and includes tick-borne encephalitis virus, Kyasanur Forest disease virus, louping ill virus, Powassan
virus, and Omsk hemorrhagic fever virus. The fourth and final clade of flaviviruses determined by this
analysis contains viruses with no known vectors and the group is named after its prototype virus, Rio
Bravo virus. Each of these clades is further grouped to both geographic location (Old World vs. New
World) and vertebrate host (i.e. birds/rodents/humans). (Gaunt et al., 2001)

1.1.2. Medically Important Flaviviruses Occurring in Florida

SLEV, WNV, and DENV are all thought to be present in FL as of 2014. WNV is known
throughout the state, SLEV is traditionally thought to be absent from southern FL but has recently been
detected as far south as Miami (FLDOH-BPHL-Tampa, unpublished data). These two viruses are thought
to overwinter in various hosts in Florida but each may currently be present only seasonally in concert with
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migratory bird populations (Rappole et al., 2000; Dunbar et al., 1998, Day et al., 1996). These migratory
birds may re-introduce WNV and/or SLEV in locales where they may have gone extinct, and although
unlikely, some years this ‘local extinction’ may arguably encompass the entirety of the state, especially in
recent years for SLEV. This absence of SLEV activity in Florida in recent years may be due to
displacement of the virus by WNV transmission, similar to what has been suggested in southeastern
California (Ottendorfer et al., 2009; Reisen et al., 2008). DENV has established limited transmission for
the first time in decades within Florida, and has caused outbreaks in Key West and Martin County. In
addition to these outbreaks, patients reporting no travel history have been diagnosed with dengue from
numerous counties in Florida during the last three years, including Broward, Hillsborough, Miami-Dade,
Monroe, Orange, and Palm Beach with no record of its sustained transmission (FLDOH, 2014).
The distribution of WNV/SLEV and DENV do not generally overlap as they exhibit different
ecologies. WNV and SLEV exhibit a zoonotic ecological pattern, whereas it is well established that DENV
transmission primarily occurs in an urban setting involving only humans and mosquitoes. In theory, the
different ecologies of the three viruses should allow Florida to support endemic transmission of each
within the state. While the ecologies of SLEV and WNV are very similar, they may differ enough in certain
reservoir hosts to escape competitive exclusion (i.e. birds/reptiles for WNV compared to birds/rodents for
SLEV). (Petersen and Barrett, 2009) Additionally, these two zoonotic viruses would likely have little
impact on the ecology of the primarily human-adapted, urban-transmitted dengue virus. This means that
Floridians may be at risk for acquiring infections with any, or all, of these viruses. Additionally, if antibodydependent enhancement of infection (ADE) occurs among different species of flaviviruses rather than just
among different serotypes of DENV, Floridians and visitors to the state may be at increased risk of severe
illness following a secondary infection of a heterospecific virus. This phenomenon of ADE is not known to
occur outside of sequential infection with heterologous serotypes of dengue, however, circumstantial
evidence supports that it may have occurred in at least one instance. A Florida man infected with WNV
succumbed to a fatal hemorrhagic fever that also had previous exposure to DENV (Paddock et al., 2006).
Furthermore, circulation of multiple flaviviruses in FL requires that functioning diagnostic capabilities be
present in order to differentially detect WNV, SLEV, and DENV. Additionally, with the onset of the Zika
virus pandemic and its subsequent introduction and local transmission in Florida, the epidemiological
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picture for flaviviruses in Florida has once again changed dramatically. One thousand fifteen (1115)
travel related-cases and 218 autochthonous cases were detected within the state during 2016 since its
hypothesized introduction that spring. However, only 80 travel-related cases and 1 locally acquired case
have been observed through October of 2017. The ecology of ZIKV is similar to that of DENV and it
remains to be seen how its introduction may affect both ZIKV and DENV transmission in Florida. (CDC,
2017; Grubaugh et al., 2017; Likos et al., 2016) Correct diagnosis of the offending viral agent is important
for managing patients in the sense of supportive care and certainly impacts vector-control measures with
regards to targeting proper vector habitats and mitigating potential outbreaks. Establishing these
capabilities takes expertise, time, research, and funding.

1.1.3. Dengue Virus (DENV)

1.1.3.1. DENV - Introduction

Infection with dengue virus continues to be a worldwide threat to public health both in human and
economic costs. In 2017, dengue virus is arguably still the most significant arthropod-borne (arbo-) viral
illness. The virus and its mosquito vectors, Aedes aegypti and Aedes albopictus, continue to encroach
upon new territory. In 2009-2010, dengue virus established its first recorded endemic transmission cycle
in the state of Florida in over a half century, first within the Florida Keys during 2009-2010, followed by an
unrelated outbreak in Martin County in 2013 (Florida Health, 2015; Munoz-Jordan et al., 2013; Anez et
al., 2012). Other recent outbreaks have occurred in the United States in Hawai’i (2002 and 2015) and
Texas (2002 and 2013) excluding outlying territories such as Puerto Rico (Johnson et al., 2016; Thomas
et al., 2016; Petersen and Barrett, 2009). Worldwide, an estimated 50-100 million infections occur
annually with an at risk global population of 2.5 billion according to WHO figures. Approximately 50,000
of these patients will progress to severe illness and require hospitalization, around 1250 of these patients
will die. (WHO, 2011) Other models suggest the current true burden of dengue at around 400 million
annual cases where approximately 100 million seek medical attention with a total of 4 billion at risk
(Gulland, 2013).
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Lack of therapeutic treatment options coupled with a vaccine in its initial stages of use in parts of
Asia and Latin America (Wichmann et al., 2017), still leaves proper clinical management as the only
primary option for reducing morbidity and mortality associated with dengue. Infection with DENV leads to
three stages of illness, the acute/febrile phase, the critical phase, followed by either recovery or
worsening to severe illness. Severe illness may include any or all of the following: hemorrhage, shock,
and/or death, but is primarily characterized by plasma leakage due to an increase in vascular
permeability. The febrile phase begins abruptly from 2-7 days after infection with non-specific symptoms.
Most often, when patients present at the clinical level during this phase, those who may progress to
severe illness and those that will experience uncomplicated illness are indistinguishable. The beginning
of the critical phase usually coincides with defervescence on days 3-7 of illness, and lasts 24-48 hours. It
is at this stage where ‘warning signs’ for development of severe illness most often become apparent and
certain patient criteria are evaluated for admitting and managing patients, ranging from presence of fever
to evidence of plasma leakage. At any stage prior to this, a diagnostic tool yet to be developed that could
identify and distinguish patients according to severity would be of tremendous value. (WHO, 2009)

1.1.3.2. DENV - History

While dengue is not a disease described in antiquity, per se, the illness itself was described long
before the causative viral agent was identified. Anecdotal evidence suggests that the disease was
described in China as far back as 992 as ‘water-poison’ associated with ‘biting flies’ as related in
Halstead, 2008 and Gubler, 1998 from a 1979 report by Nobuchi. Dengue was identified in Philadelphia
during the late 18th century (Rush, 1879), and the global picture changed after conflict in Asia due to
World War II (Brathwaite Dick et al., 2012; Gibbons et al., 2012; Halstead, 2008).
The term dengue itself proves something of an etymological problem. Break-bone fever predates
the usage of dengue and it is believed that the word is a Spanish corruption or translation of ‘dandy fever’:
the term given to the illness by displaced Africans in St. Thomas (likely slaves) circa. 1827. In turn, the
Spanish coined the term ‘el dengue’ or ‘the afflicted’ to describe the illness only one year later in Havana.
‘Dengue’ was subsequently accepted by the Royal College of Physicians and Surgeons in London as
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official nomenclature and it was further proposed that the term be Latinized to denguis, though this never
panned out. (Thomas, 1880)

1.1.3.3. DENV - Structure and Biology

Dengue disease is caused by one of four different dengue virus serotypes of small RNA viruses
in the family Flaviviridae. Each of these four serotypes are thought to have emerged from a common
ancestor, the recently discovered putative fifth serotype in Sarawak, Malaysia seems to support this
theory (Schnirring, 2013). Having emerged from a common lineage would seem to imply conservation of
common epitopes and this can be evidenced through the very narrow epidemiological picture dengue
viruses present as is currently understood (Chen and Vasilakis, 2011; Vasilakis and Weaver, 2008).
The 5’ and 3’ ends of the DENV genome contain untranslated regions (UTRs) that vary in size
according to serotype. These UTRs form secondary structures that are important in viral replication and
involve both RNA-RNA and RNA-protein interactions. Both are highly conserved among DENV
serotypes, the 5’ region contains between 95 and 101 nucleotides while the 3’ UTR of DEN1 contains 470
bases and DEN2, -3, and -4 about 385 (Gamarnik, 2010). Although highly conserved, genetic differences
do arise, for instance in the DEN3 3’ UTR, that are thought to be meaningful and may have an impact on
virulence (Goncalves de Castro et al., 2013).
The DENV genome’s open reading frame encodes, first, the three structural proteins, C, prM/M,
and env, followed by 7 non-structural proteins (Fig. 1.1). It is translated as a single polyprotein that is
processed and modified post-translationally. The first of these genes, C, encodes for the viral capsid, a
113-amino acid protein, and together make up the nucleocapsid surrounding the viral genome. The
capsid also interacts with both UTRs. The prM/M gene encodes for membrane proteins that exist in two
forms, thus the pre-membrane (prM) and membrane (M) designations. The prM is seen in immature
virions and is thought to be essential for proper folding of the env protein via chaperoning mechanisms.
The M protein is incorporated along with the env protein in mature virions to form, along with a hostderived lipid bilayer, the viral envelope. (Petersen and Barrett, 2009)
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Fig. 1.1: Representation of DENV genome by gene loci. The genome of dengue viruses, like that of all
flaviviruses, is arranged in a 5’-3’ manner and encodes, first, genes for the three structural proteins (C,
prM/M, and env) followed by 7 non-structural proteins (NS1, NS2a/b, NS3, NS4a/b, and NS5). It also
contains functional untranslated regions (UTRs) at each end of the genome (5’ and 3’). (Author’s image)
The envelope protein of DENV itself functions primarily as the major factor in the process of
infecting host cells and is the major antigenic determinant of the host immune response. In DEN1, -2,
and -4 the env protein consists of 495 amino acids and in DEN3, 493 (Beasley and Barrett, 2010). The
env protein itself contains three functional domains (I, II, and III) composed of β-barrels and exhibits
approximately 40% homology in amino acid identity across flaviviruses (Perera et al., 2008). Domain I is
located centrally and serves as a hinge region for the other two domains. Domain II contains two loop
structures and these loops function together as a site where fusion between the virus envelope and hostcell membranes occurs. This second domain is very highly conserved among flaviviruses. Not
surprisingly, antibodies generated against these loop regions are broadly cross-reactive because of this
conservation. Domain III is described as an immunoglobulin-like motif and contains four loops on its
lateral ridge. Domain III contains both conserved and species-specific sequences, thus likewise, crossreactive and highly specific antibodies are generated against it. However, this region is where the most
highly specific, strongly neutralizing antibodies are generated against DENV in humans. (Goncalvez et
al, 2010; Petersen and Barrett, 2009; Perera et al., 2008; Seligman et al, 2008)
There are 7 non-structural proteins that are encoded by the DENV genome in a 5’ to 3’ direction:
NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5. NS3 proteins consist of 618-623 amino acids and it
functions as the viral protease responsible for processing of the polyprotein. It also plays a role in viral
replication as NS3 has nucleotide triphosphatase, RNA 5’ triphosphatase, and helicase activities. It is
also the most conserved protein among the DENV group. The NS5 protein serves as the virus’ RNAdependent RNA polymerase, essential for replication, and consists of 900-905 amino acids. Potential

7

methyltransferase motifs are found at the N-terminal region. NS2A, NS2B, NS4A, and NS4B are small
hydrophobic proteins and may play roles as co-factors during viral replication and in pathogenesis.
(Beasley and Barrett, 2010; Miller et al. 2010)
The NS1 protein of DENV is found both intracellularly as well as in a soluble form (sNS1)
secreted from infected mammalian host cells and is of enigmatic function. Its immature form is that of a
monomer that can range from about 40-49kD and consists of either 353 or 354 amino acids. It readily
forms homodimers of approximately 80kD that are heat labile and usually associated with the surface of
infected cells (Beasley and Barrett, 2010; Falconar and Young, 1991). From there, the major oligomeric
form of soluble NS1 is thought to be a hexamer of around 300kD. The hexamer consists of 3 dimeric
units that are non-covalently bound and are less stable than NS1 dimers (Gutsche et al., 2011; Flamand
et al., 1999). DENV NS1 hexamers consist of a symmetric ‘barrel-shape’ that carries lipid cargo in its
central core, whereas dimer subunits are constructed around a central β-sheet domain. Monomers
consist of three domains: a small β-roll dimerization domain (aa 1-29), a ‘wing domain’ (aa 30-180), and
the predominant feature of the protein, a central β-ladder (aa 181-352). The ‘wing domain’ is surface
exposed and thought to be a major antigenic site of the protein. In fact, while this ‘wing domain’ is highly
conserved and cross-reactive with host proteins, mAbs directed at this site have shown to have a
protective effect in DENV infections. ‘Wing-domain’ derived protein subunits elict a strong enough
immune respsonse to be considered as vaccine candidates. Figure 1.2 illustrates the 3-D structure of a
DENV NS1 hexamer comprised of its constituent dimer subunits, where the lobes or ‘wing domain’ is the
dominant antigenic epitope. (Lai et al. 2017; Yap et al. 2017; Akey et al., 2014; Muller et al., 2012;
Gutsche et al. 2011; Liu et al. 2011) Secretion of the protein apparently does not abrogate replication,
however its presence is required for successful virion assembly and the ‘wing domain’ is thought to play a
critical role (Scaturro et al. 2015). DENV NS1 is variably glycosylated at two conserved sites, Asn130
and Asn207. The former site incorporates high complex glycans while the latter is found to add high
mannose glycans. DEN2 mutants lacking glycosylation at Asn207 show decreased stability but this
mutation does not abrogate dimerization. The presence of glycans at this site are also thought to
modulate secretion of NS1. Glycosylation at Asn130 is thought to help in stabilizing hexamers of NS1
and is required for interactions with proteins of the complement system. (Akey et al., 2014; Avirutnan,
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2011; Somnuke et al., 2011; Pryor and Wright, 1994) It was previously thought that NS1 was not
secreted from mosquito cells, or at least mosquito-derived cell cultures (Alcon et al., 2002; Flamand et al.,
1999) but new evidence suggests that the protein is, in fact, secreted in vector mosquitoes in a caveolindependent pathway that alters its post-translational modifications (Alcala et al. 2017).
This protein (NS1) is also thought to modulate DENV disease severity for a variety of reasons.
Secreted NS1 is thought to interact with uninfected endothelial cells, preferentially those of the
microvasculature of the lungs via heparin sulfate and chondroitin sulfate E, thus leading to capillary
leakage (Avitrutnan et al., 2007). Antibodies against NS1 are believed to cross react with human
fibrinogen and platelets, both thought to be critical factors in DENV illness, especially severe
manifestations (Arya et al., 2011; Honda et al., 2009; Falconar, 2007).

Fig. 1.2: Three dimensional (3-D) rendering of DENV NS1 protein. This figure illustrates the 3-D
rendering of DENV NS1 hexamer. In the bottom image, red, blue, and green denote dimer sub-units, the
lobes of each (‘wing domain’) are thought to be major antigenic sites for DENV NS1. Image reprinted
with permission courtesy of Paul Young. (From Muller et al., 2012)
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1.1.3.4. DENV - Virus/Vector Relationships

DENV is an arbovirus and as such is transmitted to humans via mosquitoes. However, unlike
other arboviral flaviviruses, such as WNV and SLEV, that are zoonotic in nature and where humans are
incidental hosts, i.e., not capable of developing viremia sufficient to infect a vector, the ecology of dengue
virus depends on that of humans and vector mosquitoes and both are required for establishing
transmission cycles. Therefore, the number of mosquito species serving as suitable vectors for DENV
tends to be more restrictive than that of other flaviviruses, and it is much more like YFV in this respect.
Due to the limited range of adult Aedes females, or their reluctance to search outside of their narrow
domestic habitats, the spread of DENV within a community at large is thought to be more reliant on the
movement of people. (WHO, 2009) Transmission of DENV normally occurs in humans via the bite of an
infected mosquito when the virus is injected after secretion from the mosquito salivary glands. The
extrinsic incubation period, where the virus multiplies within the vector, is typically between 10-14 days.
This type of transmission either requires the female mosquito, infectious after a prior blood meal, biting a
second human, or vertical transmission of the virus to the mosquito offspring. (Halstead, 2008)
The primary vector of dengue virus is Aedes aegypti; the ecology of this mosquito is closely tied
to that of human populations. Ae. aegypti’s habitat is thought to originally have been in Africa and its
spread to the Americas was concomitant with that of the African slave trade. Initially restricted to
Caribbean islands and port cites on the mainland, the species greatly increased its range to include the
interiors of North and South America during the early 1900s, where conditions were suitable. Upon the
initiation of the vector eradication program to combat yellow fever, it was nearly extirpated from the
Western Hemisphere. (Soper, 1967) After the crumbling of the vector-eradication program of the 1950s
and 1960s, Ae. aegypti made a remarkable comeback. Today it is present across the entire region
including parts of N. America, encompassing a range rivalling its once former peak. Both social and
climatological factors contribute to the distribution of Ae. aegypti, as evidenced throughout Latin America
and the Caribbean. (PAHO, 1997) Ae. aegypti preferentially breeds in human-generated water
containers and feeds almost exclusively on humans during the daytime. It has been described as a
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furtive feeder and may seek multiple hosts during the course of a blood meal, introducing the possibility of
mechanical transmission of DENV. (Ooi and Gubler, 2010; Halstead, 2008; Christophers, 1960)
To a lesser extent, Ae. albopictus, the Asian Tiger mosquito, is also implicated as a vector of
human transmission of DENV. The species originated in SE Asia in an arboreal setting but eventually
adapted to urban conditions, much like Ae. aegypti. For this reason, i.e. the species’ more recent
domestication, it tends to be a more generalized feeder (not as strictly anthropophilic). In recent decades,
it has greatly expanded its range, mostly via anthropogenic methods of travel and is now found on every
permanently-inhabited continent by humans. The two species have been known to co-exist in certain
locales but, on the other hand, Ae. albopictus has been also found to displace populations of Ae. aegypti.
Both situations are due in large part to the adaptation of Ae. albopictus to the preferred breeding sites of
Ae. aegypti. (Ooi and Gubler, 2010) Ae. albopictus is also a diurnal feeder but has been found to be
more aggressive in feeding than Ae. aegypti. The former is less likely to seek multiple hosts during a
blood meal due to interrupted feeding, hence its colloquial name, “Tiger” (Ooi and Gubler, 2010).
Furthermore, Ae. albopictus has demonstrated greater tolerance to colder climates and may therefore
exhibit a greater maximum range than that of Ae. aegypti. While considered a secondary vector, Ae.
albopictus is nonetheless a competent and important vector involving the transmission of DENV.
Anecdotal evidence suggests that Ae. albopictus may have contributed in the transmission of DENV to
humans to at least the mid-19th century while within its home range of SE Asia. (Paupy et al., 2009)
Aedes species other than Ae. aegypti and albopictus serve as vectors of DENV in sylvatic cycles
due to their dominant roles in vector-host relationships in these settings as compared to the former two
urban mosquito species. The collective habitats, breeding grounds, and behavior of sylvatic Aedes
mosquitoes are thought to resemble that which has been theorized for both of the above species prior to
their respective domestication. These species include, among others, Ae. luteocephalus, Ae. furcifer, Ae.
taylori (in Africa), Aedes species in the group ‘niveus’ (in SE Asia), Ae. polynesiensis (on Polynesian
islands), and Ae. triseriatus and Ae. mediovittatus (in the Caribbean). (Barrera et al., 2012; Halstead,
2008)
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1.1.3.5. DENV - Epidemiology and Ecology

The global emergence of DENV is thought to have been concomitant with the aftermath of World
War 2 (Brathwaite Dick et al., 2012; Gibbons et al., 2012; Halstead, 2008). The number of cases
detected has risen from less than 1000 from 1955-59 to approximately 1 million between 2000 and 2007.
As of 2015, an estimated 50-100 million infections with DENV occur annually. The total at risk global
population is approximately 2.5-4 billion people living within the tropics and sub-tropics. Some have
suggested, based on mathematical models, that the current annual burden of dengue contains a large
degree of error, with a range of about 75-200 million cases (Bhatt, 2013). Until very recently the only
WHO region not reporting local transmission of DENV was the European region. Over the past few years
prior to 2014, autochthonous cases have been detected in countries such as France and Germany, with
outbreaks occurring in Spain and Portugal, likely originating in Madeira (WHO, 2012).
Globally, nearly 70% (1.8 billion) of at risk populations reside within the WHO regions of SE Asia
and the Western Pacific, and most of the remaining burden occurs in C. and S. America and the
Caribbean. The Pan-American Health Organization (PAHO) subdivides the South American region;
where within the Southern Cone region alone approximately 98.5% of cases are reported from Brazil.
Outside of the Southern Cone, within the Andean region, 81% of DENV cases are reported from
Colombia and Venezuela, a region showing many similarities to that of most of Brazil (WHO, 2009).
These two countries also possess both the overland gateways to S. America as well as important ports.
In 2008 the combined region of the Caribbean, Mexico, C, and S. America reported 908,926 cases of
dengue. (PAHO, 2011) In North America prior to 2009, indeed even after, the areas most at risk of local
transmission are those bordering endemic regions and those experiencing high levels of traffic between
endemic regions. For instance, areas where local transmission have occurred include Hawai’i (distant to
the mainland in the ‘Western Pacific’) along the border between Texas and Mexico, and in Florida
(adjacent to the Caribbean region). These areas are all connected to endemic regions and experience
high-levels of movement of people between endemic and non-endemic areas. (Munoz-Jordan, et al.,
2013; Anez et al., 2012; Petersen and Barrett, 2009; Rawlings et al., 1998)
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As of 2008 most countries in Latin America and the Caribbean reported at least two circulating
serotypes of dengue. Among these countries are Brazil, Mexico, and Puerto Rico (USA): places that are
well documented to have issues with dengue transmission. By 2013 most countries within contiguous
Central and South America have indeed reported all four circulating (Fig. 1.3) (PAHO, 2011). It should be
noted that generally the burden of dengue is lower in the Caribbean than in contiguous Latin America.
Economic disparity between island nations of the Caribbean also seems to play a role as the poorer
nations are generally subjected to the highest burden of cases. In Florida, other than typical factors such
as travel, the presence of competent vector populations, and population density, specific factors that may
lead to autochthonous transmission of DENV remain unclear and is being actively investigated (MunozJordan et al., 2013; Anez et al., 2012).

Fig. 1.3: Distribution of DENV serotypes in the Americas, 1990-2013. These maps illustrate the
number of DENV serotypes present in the Americas from the time period 1990-2013 using data from four
representative years. Note that by 2013 all four serotypes were found to be present in nearly the entire
region south of the United States. (PAHO, 2014)
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1.1.3.6. DENV - Importance in Florida

After a 75 year absence, local transmission of DENV was documented in Florida, initially during
an outbreak of DEN1 (genotype V, clade E) in Key West during 2009-2010. It is now considered as
triansiently present within FL. One-hundred and three (103) autochthonous cases were documented in
the time period between 2009-2012 with the majority of those cases (27 in 2009 and 63 in 2010)
associated with an outbreak in Monroe County (Key West). However, epidemiologically unrelated,
locally-acquired cases were also documented in Broward, Hillsborough, Miami-Dade, Palm Beach,
Osceola, and Seminole counties through 2012. An additional outbreak of a genotype not derived from
the Key West strain occurred in Martin County during 2013. (Florida Health, 2015; Anez and Rios, 2013;
Munoz-Jordan et al; 2013; Adalja et al., 2012; Anez et al., 2012) Two introductions of local transmission
thus are thought to have occurred in Martin County, the first near Port Salerno in 2011 and the second
near Jensen Beach; the latter introduction was responsible for the outbreak (Florida Health, 2015). In
2016, an autochthonous case of DEN4 (Cone, personal comm.). Another dengue case was detected in
Miami-Dade during the 2016 Zika virus outbreak investigations and was found to be locally-acquired
(Florida Health; 2016; Miami Herald, 2016).
Within Florida, the Miami metropolitan area is arguably the area at highest risk for introduction of
the virus. However, limited transmission has, in fact, occurred in the area, as some isolates from the area
match sequences derived from the 5’ end of the genome (C and prM/M respectively) of isolates obtained
from the Martin County outbreak (genotype V, clade C) (Munoz-Jordan, et al., 2013). Although focusing
on specific genome regions may more easily identify genotypic differences, it has been asserted by
Christenbury et al. (2010) that for epidemiological reasons, a method for rapid full-length genome
sequencing be implemented to better elucidate transmission patterns in epidemic situations.

1.1.3.7. DENV - Control Measures

Before 2015 when a licensed dengue vaccine for all four serotypes became available on the
market in a number of countries, control of vector populations was the only method available to combat
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DENV transmission. The control of dengue was unamenable to both preventive and prophylactic medical
interventions. The efficacy and safety of the available vaccine remains to be seen but has shown
promise. (Wichmann et al., 2017; Petersen and Barrett, 2009) While vector-control measures have
proven successful where there is adequate infrastructure in place, this is severely lacking in a large
portion of the world. There are issues with many ‘blanket approach’ vector-control measures that affect
the local ecology, sometimes detrimentally (e.g., DDT), and that they must be undertaken indefinitely
(Patterson, 2004). Vector control measures include mechanical, chemical, and biological methods. The
favored means of each, respectively, include the removal of standing water from potential breeding sites,
fogging with the organophosphate pyrethroid, temephos, and treatment with aerial spraying of Bacillus
spp., notably Bacillus thuringiensis isrealensis and B. sphaericus, which target mosquito larvae.
However, due to limitations of each approach and the benefits associated with using multiple approaches,
an integrated approach to vector control is currently favored. (Becker et al., 2003) Novel approaches to
vector management via biological methods include transgenic modification to reduce mosquito
populations and the reduction of vector competency via methods such as the introduction of symbionts or
parasites. (Patterson, 2004; Becker et al., 2003) For instance, a UK firm, Oxitech, has recently released
male-lethal genetically modified (GM) Ae. aegypti mosquitoes (OX513A) in the Cayman Islands,
Malaysia, Brazil, and Panama, with trials also set to occur in Key West, FL (NPR, 2016; Carvalho et al.,
2015; Gorman et al., 2015; Winskill et al., 2015; Harris et al., 2012; Lacroix et al., 2012; Harris et al.,
2011). The major questions regarding this approach and other vector modifications is related to fitness
and longevity, however dramatic reductions in Ae. Aegypti populations have been observed in the short
term due to the release of these GM mosquitoes. What will occur over the long term at release sites
remains to be seen.
While vector control methods for combatting dengue transmission are time-proven and effective,
they cannot universally prevent or eliminate dengue. As with most infectious disease entities, a vaccine
remains the ‘silver bullet’. Wichmann et al., 2017 and Webster et al., 2009 provide thorough reviews of
the development, progress, and remaining questions regarding dengue vaccines. Briefly, each group
details that there are at least 12 different vaccine candidates for dengue virus in various stages of
licensure, clinical trials or pre-clinical development. A chimeric, infectious preparation (ChimeriVax) that
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includes prM and env proteins of the four DENV (and is thus tetravalent) successfully underwent phase 3
clinical trials and is now licensed for use in a number of countries in Latin America and Asia under the
trade name Dengvaxia® (Sanofi Pasteur, Swiftwater, Pennsylvania). Each group also discusses other
developments; there are two each of monovalent vaccines prepared from live-attenuated and infectious
clones, respectively. Preparations using immunogenic viral proteins, viral DNA, and complete vaccines
using either inactivated virus or recombinant technologies (replication incompetent, virus vectors) are also
in development. A functional, efficacious DENV virus vaccine would be of enormous value and reduce
the burden on, or the need for, all other control measures.

1.1.3.8. DENV - Clinical Disease and Pathogenesis

DENV causes a spectrum of illness in humans from a mild febrile presentation all the way through
to fatal outcomes. Infection may also be asymptomatic. A minority of patients may progress to severe
illness where the development of hemorrhagic complications and/or shock may occur late. (WHO, 2009)
The main type of cell infected by DENV is thought to be dendritic cells (DCs) after inoculation of the host
via mosquito (Boonak et al., 2010; Sun et al., 2009; Boonak et al., 2008). Migration of these infected cells
to regional lymph nodes is then thought to lead to systemic infection where cells such as hepatocytes and
endothelial cells (ECs) may also be infected or play a role in pathogenesis (Azizan et al., 2009; Azizan et
al., 2006; Peyrefitte et al., 2006; Dewi et al., 2004). In secondary infections, monocytes and
macrophages are thought to play an additional source of infection, and play an extremely important role in
the onset of severe illness (Wati et al., 2007).
Antibody-dependent enhancement (ADE) of infection is the current dogma that most dengue
researchers adhere to with respect to the development of severe pathogenesis. The ADE model was
based on field observations by Halstead, 1976 referring to the preponderance of Thai patients that
manifested severe illness upon secondary, heterotypic infections with dengue. In this theory, nonneutralizing cross-reactive antibodies produced in response to a primary infection with dengue virus are
thought to increase the severity of illness in heterotypic, secondary DENV infections. FcγR-bearing cells
such as those of the monocyte/macrophage lineage are thought to be the primary cellular targets in ADE
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via intracellular viral escape from virus-antibody complexes once endocytosed (Boonak et al., 2010;
Honda et al., 2009; Boonak et al., 2008; Chen et al., 2008; Fink et al., 2006; Huang et al., 2006; Kontny et
al., 1988). Uptake into and subsequent virus replication within these cells is thought to elicit a
maladaptive cytokine response, termed the ‘cytokine storm’, that ultimately produces the vasculopathy
that is the hallmark of severe cases (Basu and Chaturvedi, 2008; Fink et al., 2006). Provided that
normally targeted cells, such as dendritic cells are also still infected, ADE should therefore increase the
total viral load, however the opposite seems to be true (de la Cruz-Hernandez et al., 2013; Tricou et al.,
2011). Alternatively, chemotactic cytokines such as monocyte chemoattractant protein 1 (MCP-1), that
have been found to be upregulated in severe illness (Lee et al., 2006), may also serve to increase the
number of infected cells by recruiting newly susceptible monocyte-derived macrophages to infected cells
(Sierra et al., 2010). The infection of these recruited cells would then be dependent on the co-localization
of non-neutralizing antibody. Cells of the liver and the endothelium are also known to play a role in ADE
but whether through direct infection or some other means remains to be seen (Avirutnan et al., 2007).
The exact molecular mediators involved in ADE and the direct roles of other implicated cell-types have
been intensively investigated yet not fully elucidated.
Cytotoxic T-cells have also been implicated in severe illness, such as those low-avidity crossreactive types that are induced in ADE, but again their exact role is unclear. CD8+ T-cell mediated
cytotoxicity is coincident with a shift to a T H1 mediated response. It is thought that secondary infections
with DENV exhibit a shift to cell-mediated immunity, likely after the initial memory-induced humoral
response, and that this response is damaging. This theory does not require the infection of macrophages
or other Fcγ-receptor cells for the development of severe illness, but may in fact be exacerbated by ADE.
A shift to cell-mediated immunity would be unlikely after an appropriate humoral response and would
require an active (non-neutralized) infection. (Basu and Chaturvedi, 2008; Dong et al., 2007) The
expansion of low affinity CD8+ T-cells that are inefficiently cytotoxic in secondary infections would seem
to support this idea of a continuous and inappropriate response (Fink et al., 2006). This shift to cellmediated immunity was found to be concurrent with defervescence in 20 Indian dengue patients, thus at
a time of decline in viral titers. Numerous pro-inflammatory mediators were found to be produced in these
same 20 Indian patients. Furthermore, 10 patients with severe illness had elevated levels of intracellular
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macrophage inflammatory protein 1 alpha (MIP-1α) and IFN-γ compared to the 10 non-severe cases,
indicating upregulation of these cytokines. (Kadhiravan et al., 2010) This should not, however, discount
the role that cytotoxic T-cells may play in the development of severe pathology, instead, that their role
also seems to be closely tied to secondary infections.
Alternatively, cytotoxic T-cells may contribute to pathogenesis when there is greater viral burden
(regardless of mechanism) by inducing cell death and the subsequent release of elevated levels of
previously intracellularly sequestered viral proteins. These proteins in turn would be presented in an
MHC-I manner to additional CD8+ T-cells that can be activated to produce more soluble mediators further
downstream, again in an elevated response. This was evident in a study that found a large proportion of
T-cells reactive for DENV NS3 protein in peripheral blood mononuclear cells (PBMC)s of Thai patients
with severe dengue. DENV NS3 protein functions as a serine protease, is involved in processing the viral
polyprotein, and would almost exclusively be found intracellularly, although this phenomenon would seem
to require some amount of surface expression. (Duangchinda et al., 2010) The elevated detection of
various cytokines that are produced mainly via cytotoxic T-cells both in vitro and in vivo indicating severe
illness also implicates a role for CD8+ T-cells (Basu and Chaturvedi, 2008; Fink et al., 2006).
The generation of normally beneficial inflammatory mediators in quantities that become damaging
has been found as a mechanism involved with severe dengue pathology. The generation of a ‘cytokine
storm’ is not exclusive from other proposed mechanisms, and in fact would be dependent on the
occurrence of at least one mechanism acting upstream. While the sequence of cascades and the exact
players involved have yet to be fully elucidated, TNF-α and IFN-γ seem to be two of the most important
mediators and are often elevated in severe illness. (Basu and Chaturvedi, 2008; Fink et al., 2006) ILs1β, 2, 4, 6, 8, 10, 12, macrophage migration inhibitory factor, granulocyte-macrophage colony stimulating
factor (GM-CSF), MCP-1 or CCL2, elastase, sTNFR, regulated and activated upon normal transcription
expressed and secreted (RANTES), MIP-1α, MIP-1β, sIL-2R, IL-1ra, interferon-γ inducible protein (IP)-10
or CXCL10, soluble intercellular adhesion molecule (sICAM-1), soluble vascular cell adhesion molecule
(sVCAM)-1, and vascular endothelial growth factor (VEGF) have all been implicated to play a role in
severe illness and more appropriately illustrate the ‘storm’. (Appanna et al., 2014; Rathakrishnan et al.,
2014; deOliveira-Pinto, et al., 2012; Gupta et al;, 2012; Puerta-Guardo et al., 2012; Thayan et al., 2010;
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Azizan et al., 2009; Sun et al., 2009; Basu and Chaturvedi, 2008; Boonnak et al., 2008; Chen et al., 2008;
Restrepo et al., 2008; Yen et al., 2008; Azizan et al., 2006; Halstead, 2007; Dong et al., 2007; NE Reis et
al., 2007; Azizan et al., 2006; Fink et al., 2006; Shmitt et al., 2006 Shresta et al., 2006; Lin et al., 2005;
Mangada and Rothman, 2005; Avila-Aguero et al., 2004; Dewi et al., 2004; Bosch et al., 2002; Suharti et
al., 2002).
In a Malaysian study (Appanna et al., 2012), cytokine profiles were measured for 27 different
markers in 13 classical dengue patients and 29 DHF patients against 6 healthy individuals. These
profiles were measured at different time intervals, including 2-3, 4-6, and more than 7 days after onset for
patients. One curious result was that IFN-γ was seen to be elevated in DHF patients versus non-severe
cases for the duration of illness. The production of IFN-γ in these non-severe cases was also lower than
that for healthy controls. This study also showed that IP-10, RANTES, MCP-1, MIP-1β, and ICAM-1 were
generally more pronounced in DHF patients, followed by non-severe cases, and then healthy controls;
these responses were individually time-dependent. Furthermore, DHF patient sera was found, by
confocal microscopy, to be responsible for altering the tight junctions of vascular endothelial cells more
profoundly than non-severe cases and healthy individuals. The fact that vascular permeability goes hand
in hand with the development of shock shows that this particular result supports current theories of severe
DENV pathogenesis. There was no mention in this study of specific infecting serotype nor direct mention
of previous infection status.
A study in the Philippines, by Chagan-Yasutan et al., 2013, took a similar approach with respect
to measuring cytokine and chemokine levels in DENV infected patients but also chose to focus on levels
produced during the ‘critical phase’ to assess predictive values for progression to severe disease. Here
they assert that the increased levels of Galectin-9, IFN-α2, eotaxin, and MCP-1 were capable of
predicting 92% of DHF cases (out of 29 potential markers) although when averaged among all DENV
patients there were a number of markers that were more elevated or equally elevated as these four. A
Colombian group, in Restrepo et al., 2008, further asserts that these responses to infection with DENV, at
least a proportion of them, may be related to ethnicity. Colombian Mestizos showed an altered response
to infection than Afro-Colombians with respect to production of TNF-α and IL-6. On the other hand, IFN-γ
production was only seen to be elevated in DHF cases over non-severe cases, regardless of ethnicity. It
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is unclear, what, if any, confounding factors exist between these populations aside from ethnic
background.
It cannot be overstated that it is desirable that a form of ‘reference values’ exist for these markers
in determining potential outcomes of DENV illness. One of the biggest questions regarding the
manifestation of shock is the degree of involvement of endothelial cells (ECs) and may be answered by
analyzing cytokine responses (Appanna et al., 2012; Dalyrymple and Mackow, 2012; Azizan et al., 2009;
Yen et al., 2008; Azizan et al., 2006; Lin et al., 2005; Dewi et al., 2004; Huang et al., 2000). If endothelial
cells are productively infected and cell death occurs, or if they are damaged in some indirect way, then
plasma leakage is a direct result of damage to the vasculature rather than actions of the ECs themselves.
Endothelial cells have been infected with DENV in vitro, but the occurrence of this in vivo is questionable.
Uptake of virus-antibody complexes by ECs has been noted to induce cytotoxic mediators (Fink et al,
2006). Indirect (bystander) damage to the vasculature has been implicated by numerous inflammatory
mediators such as reactive nitrogen and oxygen species, TNF-α, IFN-γ, and as discussed below,
complement (Basu and Chaturvedi, 2008; Fink et al., 2006). Importantly, self-treatment with over-thecounter drugs such as aspirin may also contribute to complications such as hemorrhage (Valerio et al.,
2006). Other serum markers indicative of angiogenesis may be directly linked to repairing damage to the
vasculature.
Upregulation of vascular endothelial growth factor (VEGF) in DENV infected HPMEC endothelial
cells has been demonstrated in vitro and has been found to be elevated in human sera (Azizan et al.,
unpublished data; Azizan et al., 2009; Azizan et al., 2006). However, the detection of VEGF as a serum
marker in a significant quantity of patients that have developed severe illness would be desirable. It has
also been noted that studies attempting these analyses may be hampered by extravasation of serum
markers if sampling during shock and thus difficult to accurately measure (Kadhiravan et al; 2010). The
way in which shock may arise is due to induction by the host, perhaps in direct response to the damaging
‘cytokine storm’. This would indicate the involvement of endothelial cells during DENV infection being
limited to the temporary relaxation of the tight junctions responsible for maintaining vascular integrity
through mediators such as histamine and prostaglandins. Both phenomena play a role in the
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development of plasma leakage and shock in severe dengue illness (Fink et al., 2006). Finally, it is noted
by most, that the limitations of these individual studies are small sample sizes.
Complement in the form of the membrane attack complex (MAC) as well as anaphylatoxin (C5a)
may also play a role in the development of severe illness (Shresta, 2012). DENV NS1 may be
responsible for this association as levels of both complement products were shown to be positively
correlated with levels of NS1 in 9 Thai patients with shock (Avirutnan et al., 2006). C5a has both a direct
and indirect effect on increasing vascular permeability (Moore, Jr., 2004). Complement, NS1, antibody
generated to NS1, and platelets also appear to interact in a manner that promotes severe illness. AntiNS1 antibodies apparently cross-react with platelets and subsequently induce lysis via complement
leading to coagulopathy. This coagulopathy, if sufficient, promotes the development of hemorrhage
and/or plasma leakage. These cross-reactive antibodies are of the IgM class indicating an acute, often
primary infection, as IgM is often undetectable in secondary cases. (Fink et al., 2006) Perhaps this
interaction is largely dependent on virus burden only, as suggested by the association with serum levels
of NS1 and the acute chronology of the phenomenon.
ADE has been documented in vitro but has been difficult to assess in humans (Midgley et al.,
2011; Halstead, 2007; Halstead et al., 1983; Halstead and O’Rourke, 1977). Support for this theory
further comes from epidemiological data demonstrating increases in severe illness following sequential
introductions of heterotypic dengue serotypes in naïve populations. This was seen in Cuban epidemics
after introduction of DEN2 (1982) and DEN3 (1997) following the original introduction of DEN1 (1977)
(Guzman et al., 2010; Halstead, 2007). It is currently unknown if ADE extends to other non-DENV
members of the Flaviviridae. It has not been documented in JEV or YFV vaccinees subsequently infected
with DENV, yet it may or may not occur in both. ADE may have indeed occurred in a natural WNV
infection whereby a Florida man with pre-existing antibody to dengue succumbed to a fatal, and most
unusual, hemorrhagic WNV infection (Paddock et al., 2006). WNV is not known to cause this type of
pathology in the Western hemisphere.
Another theory attempting to describe the manifestation of severe DENV illness, is that based on
viral load. The theory that increased viral load mediates severe illness holds that the higher the titer of
virus that is generated, the greater the chance of developing severe disease (Gubler et al., 1981).
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Increased viral burden may arise in numerous ways. For instance, increased viral load may be a
consequence of ADE. However, it has been noted in studies that secondary cases result in both
decreased peak viremia as well as lower levels of DENV NS1 antigenemia (Tricou et al., 2011).
Increased viral burden is also dependent on the infecting dose and may be affected in one of two ways.
A mosquito may itself have a greater viral load, or a person may become ‘hyper-infected’ from multiple
mosquitoes. An increase in viral load may also be conferred by either, or both, host and virus genetics in
some as yet undetermined way (Guzman et al., 2010). A total increase in viral load may have one of two
effects: the immune response may be greatly amplified, becoming maladaptive and damaging, or viral
progeny may overwhelm the immune system, directly causing an increased amount of cell death.
Elevation of cell-mediated cytotoxicity, in addition to a ‘cytokine storm’ may both result from increased
viral burden. Evidence for this mechanism at work in dengue patients in a Taiwanese study showed that
increased viral burden resulted in both a delay of viral clearance and increased detection of virusantibody complexes in 49 DEN2 patients suffering from severe illness compared to 54 cases of
uncomplicated forms; all of these patients were determined to have secondary infections (Wang et al.,
2006). C5a and the membrane attack complex (MAC), also discussed above, were found to be elevated
in severe cases. This can be taken in conjunction with reports that elevated levels of DENV NS1 protein
(a surrogate marker for increased viral burden) positively correlate with the development of severe illness.
(Avirutnan et al., 2006; Libraty et al., 2002).
Host genetics likely plays a part in severe cases but the current paucity of data does little to
enhance our understanding of what factors may predispose an individual to developing severe illness.
Human leukocyte antigen (HLA) type has been implicated by observations that people of African descent
appear to have some measure of protection from developing severe manifestations of dengue and a
number of polymorphisms seem to partially confirm this (Guzman et al., 2010; Fink et al., 2006). A single
nucleotide polymorphism (SNP), AA to AG, in the gene encoding for DC-SIGN (a putative receptor for
DENV) may in fact predispose an individual to severe illness. Dendritic cells derived from 20 Taiwanese
volunteers bearing the AG genotype showed increased DC-SIGN expression, TNF-α, IL-12p40, and IP-10
production, yet decreased viral replication compared to those derived from the AA SNP. In the same
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study, analysis of a Taiwanese cohort of dengue patients also showed significant association of severe
illness with the polymorphisms AG or GG. (Wang et al., 2011)
As there is a mechanistic threshold separating uncomplicated dengue from severe illness, there
should also be one separating DHF and DSS. This could simply be attributed to additionally elevated
viral loads and/or cytokine responses (Appanna et al., 2012; Rathakrishnan et al., 2012; Dalyrymple and
Mackow, 2012; Azizan et al., 2009; Sierra et al., 2010; Yen et al., 2008; Azizan et al., 2006; Lin et al.,
2005; Dewi et al., 2004; Suharti et al., 2002; Huang et al., 2000). Alternatively, it may be that DSS is
predominantly mediated through some undetermined host genotype, such as inconclusive investigations
of polymorphisms within the TNF-α gene (Guzman, et al., 2010). However, there is no consensus model
for describing the precise cascade of events leading to the development of shock in severe cases of
dengue. This may be because, from what can be assessed from the literature, that there is no single
model that describes the phenomenon as it occurs in vivo. Nevertheless, one of the major players in
producing severe illness is tumor necrosis factor alpha (TNF-α). Synergistic effects of TNF-α with
cytokines such as interferon (IFN)-γ and interleukin (IL)-8 have been under investigation in the
development of DENV illness. (Sierra et al., 2012; Restrepo et al., 2008; Yen et al., 2008; Talavera, et
al., 2004)
TNF-α is a potent mediator of inflammation and possesses a variety of signaling capabilities.
TNF-α is also considered a pyrogen in that it induces fever and has anti-angiogenic properties. These
properties serve to make it an important factor in dengue associated shock. It is a basic protein that
associates into 3 subunits existing in two forms; the first is a 27 kD membrane bound form. This
membrane-anchored protein, mTNF-α, may then undergo proteolytic cleavage by the metalloprotease,
TNF-α converting enzyme (TACE), to form the soluble, 17 kD form, sTNF-α. The membrane bound form
primarily acts in an autocrine/paracrine manner, while the secreted form functions in an endocrine
capacity. (Parameswaran and Patial, 2010) The most significant producers of TNF-α include monocytes
and macrophages. These cells are also thought to be important mediators in the development of severe
illness with dengue virus (DENV) infection. (Vinh and Holland, 2009) Two different receptors that bind to
TNF-α, TNFR1 and TNFR2, are expressed on different cell populations. TNFR1 is expressed rather
ubiquitously on most cell types, while TNFR2 is limited to expression on cells of lymphoid origin.
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Importantly, TNFR2 is fully activated only in the presence of mTNF-α and not sTNF-α, necessitating direct
cell-cell interactions. Chemotactic molecules produced in response to DENV infection can thus have an
impact of the likelihood and degree of TNFR2 activation. Upon binding of its cognate receptors, TNF-α
initiates a number of distinct intracellular processes via cascade events. The downstream effects of gene
regulation through TNF-α signaling are multifarious, but can be broken down into two ultimate effects, one
promoting apoptosis and the other cell survival. Apoptosis is mediated through binding of TNFR1 and
the production of caspase8. Conversely, binding of TNF-α to either receptor may lead to anti-apoptotic
effects, proliferation of immune effector cells, and subsequent production of inflammatory cytokines.
(Parameswaran and Patial, 2010)
Monocytes/macrophages are thought to be both the major producers of TNF-α and the major
target cells for dengue virus in severe illness. Therefore, it is reasonable to conclude that the response of
these cells to infection may lead directly to an increase in vascular permeability and development of
shock under certain conditions (Fig. 1.4). Most studies implicate a major role for TNF-α and,
subsequently, IL-8, as levels of these cytokines have been found to be elevated in DENV infections and
extremely elevated in severe illness (or models of severe illness). One consequence of the activation of
nuclear factor (NF)-κB by TNF-α includes the downstream production of the cytokines IL-6 and IL-8. NFκB promotes inflammation and a general anti-apoptotic state and this is mediated in large part via the
production of TNF-α. The increase in vascular permeability has been also found to be positively
correlated with a number of markers indicative of extravasation of these phagocytic cells such as MCP-1
and ICAMs. (Basu and Chaturvedi, 2008; Lee et al., 2006). As previously mentioned, IFN-γ production
has been found to be upregulated in severe illness but other authors have found the converse to be true
as well (Basu and Chaturvedi, 2008). The former would seem to make more sense as IFN-γ has been
found to act synergistically with TNF-α to increase vascular permeability (Pang et al., 2007). Elevated
concentrations of TNF-α and/or IL-8 have been demonstrated in DENV patient serum, murine models,
and various in vitro models including endothelial cells, epithelial cells, monocytes, macrophages, dendritic
cells, and T-cells (either in direct response to infection or through interactions with infected cells) (Sun et
al., 2009; Boonnak et al., 2008; Chen et al., 2008; Restrepo et al., 2008; Yen et al., 2008; Dong et al.,
2007; Azizan et al., 2006; Shresta et al., 2006; Dewi et al., 2004; Bosch et al., 2002). Additional models
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have shown the importance of TNF-α through use of treatments such as dexamethasone, ribavirin, and
leaf extracts from Hippophae rhamnoides. Treatment with these compounds resulted in increased cell
viability and/or decreased viral load with subsequent lower levels of TNF-α production (Jain et al., 2008;
NI Reis et al., 2007).

Fig. 1.4: An immunological model for the pathogenesis of severe dengue (DHF/DSS) and
coincident vasculopathy. It is thought that DENV infected macrophages (Mφ) play a dominant role in
the ultimate vasculopathy witnessed in severe manifestations of dengue due to their pluripotent roles as
immune-effector cells. This includes but is not limited to: their ability to uptake incompletely neutralized
virus in a heterotypic, secondary DENV infection which leads to infection of the Mφ and the resultant
cytokine response; as well as their role as antigen presenters which aslo result in cytokine production,
here due to the recruitment of T-cells. These cytokines further act upon the vascular endothelium
resulting in damage and/or an increase in permeability due to relaxtion of gap junctions. This ultimately
leads to plasma leakage and shock. (Adapted from Fink et al., 2006.)
1.1.3.9. DENV - Diagnosis and Prognosis of Infection

Heart rate (bradycardia), positive tourniquet tests, demonstration of pleural effusion (via X-ray or
sonogram), liver enzyme levels such as elevated serum transaminase, altered hematocrit levels, as well
as hemoglobin, white blood cell, and platelet counts are all used in determining pathogenesis in DENV
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infected patients (Fig. 1.5) (WHO, 2009). In a study of 100 serologically dengue positive patients, these
methods were found to be capable of predicting dengue in 81% of patients without the use of traditional
confirmatory methods of diagnosis. However, only elevated liver enzymes, specifically, aspartate
aminotransferase (AST) was seen in more than seventy percent of patients (73%). Individually, these
tests appear less predictive as a smaller proportion of patients exhibited one ‘hallmark’ or another, in
descending order: pleural effusion (63%), leukopenia (57%), elevated alanine aminotransferase (ALT,
43%), positive tourniquet test (40%), hematocrit levels >45% (32%). Another marker but one less
acknowledged in the literature, gall bladder wall edema, was observed in 87% of patients and increased
the overall predictive value of these non-confirmatory tests. (Manimala Rao, 2014) On the other hand,
the fact that this study did not focus on different outcomes of DENV disease in their predictions, i.e. nonsevere versus severe outcomes, seems to unfortunately devalue some of the collective tests prognostic
utilities. For instance, a progressive increase in hematocrit levels concomitant with progressive
thrombocytopenia is considered as a ‘warning sign’ of severe dengue according to WHO guidelines.
(WHO, 2009)
Patient IgG and/or IgM ELISAs are still the most widely used and preferred method for confirming
diagnosis with dengue. However, only 50% of patients will display detectable levels of IgM, indicative of
an acute, usually primary infection, by days 3-5 after onset. IgG only becomes detectable 1 week after
illness onset and requires two samples for confirmation (acute and convalescent). In secondary cases,
where patients are more likely to develop severe illness, IgG is detectable at onset but only reaches peak
titers 7-10 days after onset of illness. Acute and convalescent samples are still required for confirmation
(Fig. 1.6). IgM is usually barely detectable during the acute phase of secondary cases and titers do not
normally increase significantly. A number of traditional, end-point and real-time RT-PCR assays have
been developed for detection of dengue virus RNA in patient sera, now including one real-time assay
approved by the FDA for use in US laboratories. RT-PCR has been useful for confirming acute dengue
infection as peak viremia, and thus levels of viral RNA, occurs prior to development of antibodies (Fig.
1.7), importantly DENV NS1 levels show a similar profile and can be detected by ELISA (Fig. 1.8). RTPCR requires more expensive equipment and much more stringent handling of samples and thus is not
as widely used as ELISA. It is also of little prognostic value on its own, as higher levels of viremia do not
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always correlate with greater disease severity. However, it is confirmatory and is capable of informing
infecting serotype. (WHO, 2009)
Obtaining and transporting appropriate samples has also been an obstacle in DENV diagnostics.
Whole blood, serum, and/or plasma samples have been the norm for all of the above assays.
Cerebrospinal fluid (CSF) has not traditionally been sought to diagnose DENV but testing has been
shown to be useful after ruling-out other arboviral illnesses, especially since dengue has been shown to
cause neurological illness in rare cases (Goswami et al., 2012; Gulati and Maheshwari, 2007). IgM and
DENV NS1 have been detected by ELISA in the CSF of fatal cases of infected individuals, though not all
involved in the study (Araujo et al., 2011). Proper collection and handling of these samples, e. g.,
maintaining cold-chain procedures and obtaining follow-up specimens, is sometimes difficult and
therefore other types of samples have been investigated for use in DENV diagnostics. Dried blood
samples collected on filter paper has shown promise in detecting anti-DENV IgM and IgG as well as NS1
antigen. Oral swabs have shown less promise but may be useful in detecting anti-DENV IgA, although
interpretation of results may be difficult (Anders et al., 2012; Nawa et al., 2005). Results, such as those
reported in Anders et al., 2012, assert that DENV-specific IgA detection is superior in serum and
bloodspots rather than oral swabs.
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Fig. 1.5: WHO criteria for establishing patients with dengue exhibiting warning signs and those
experiencing severe dengue. This figure illustrates four levels of dengue patient diagnosis and
prognosis from: 1. probable dengue 2. laboratory confirmed dengue (both for diagnosis) 3. dengue with
warning signs and 4. severe dengue (both for prognosis). (WHO, 2009)

Fig. 1.6: Suggestive versus confirmatory laboratory results for determining infection with DENV.
Confirmation of DENV infection can only be achieved in the laboratory by one of four routine methods: a
positive PCR result, isolation of virus and evidence of seroconversion in paired sera via IgM or IgG (a
fourfold increase in IgG titer is also sufficient). Positive IgM and/or IgG results in single serum samples
are considered suggestive only. (WHO, 2009)
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Fig. 1.7: Clinical profile of DENV infection by several parameters. This diagram shows the clinical
profile of the different markers and outcomes of infection with DENV according to the following
parameters by days post onset: fever (temperature), hematocrit levels, platelet counts, viremia, and antiDENV IgM levels. It is a desirable goal that patients that would proceed to into shock (shaded area, days
4-6) be identified by some method at a time around peak viremia and fever (days 1-3) in order to ensure
proper clinical management. (WHO, 2009)
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Fig. 1.8: Clinical profile of DENV infection by several parameters. This diagram shows the clinical
profile of the different markers of infection with DENV (via sensitivity of assay) according to the following
parameters by days post onset of fever: viral detection, NS1 detection, IgM detection, and IgG detection.
The left image illustrates profiles for primary DENV infections and the right, non-primary infections. Note
that NS1 detections compares favorably to detection of virus in acute cases (especially those that are
primary infections). (CDC, 2015)

1.1.3.9.1. Traditional Methods of DENV Diagnosis

1.1.3.9.1.1. Serological Methods of DENV Diagnosis

Serological assays have been the mainstay of DENV diagnostics since their inception and have
traditionally been the means used by the FLDOH BPHL-Tampa laboratory (Stark, personal comm.). The
standard assay has been detection of antibody to DENV via enzyme-linked immunosorbent assay
(ELISA). This assay is useful for detecting acute primary and secondary cases as well as past exposure
based on the resultant serological profiles. Detection of IgM in acute cases is one of the more useful
approaches, especially in primary infections. IgG profiles may also be determined through ELISA but
require acute and convalescent sera, most often leading to confirmation after resolution. IgG positive
individuals may also indicate previous infection based on profile. However, a marked elevation of IgG
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occurs in secondary cases during the acute phase due to the induction of non-neutralizing antibodies
generated against heterologous serotypes from previous infections. (WHO, 2009) Due to the (hyper)
endemic status of DENV in regions where it circulates it has been difficult to ascertain the longevity of
circulating antibody. It is thought to be long lasting though, as it has been reported that four individuals
retained circulating antibody to DEN1 after more than 60 years of exposure centered on the outbreak of
1944-1945 in Hawai’i (Imrie et al., 2007).
The hemagglutination inhibition assay (HAI) is also suitable for diagnosing DENV infections. This
assay traditionally consists of an antigen (usually produced in suckling mouse brain), antibody from
patient samples, and goose erythrocytes. These erythrocytes will agglutinate in the presence of certain
antigens, including those of DENV. The formation of antigen-antibody complexes prior to treatment with
the red blood cells leads to the inhibition of agglutination. Therefore, acute infections are often evidenced
by the lack of agglutination after multiple dilutions of the patient sample indicating high circulating titers of
antibody. This test is less specific then ELISA as there is significant cross reactivity among the
flaviviruses. (Petersen and Barrett, 2009; Perera et al., 2008; Seligman, 2008; Calisher et al., 1989)
The serum-neutralization plaque-reduction (SNPR) assay, also called the plaque-reduction
neutralization test (PRNT) is a confirmatory assay of DENV infection. The WHO provides a guide for this
assay in an attempt to reconcile procedural variations while issuing forth minimum requirements (WHO,
2007). In this assay cell cultures are first inoculated with a standardized titer of virus previously incubated
with varying dilutions of human sera potentially containing neutralizing antibody. These cultures are then
overlaid with a semi-solid agarose-based medium and further treated with a dye that demarcates areas of
infected cell death (plaques). Sera lacking specific antiviral antibody show no reduction in the number of
plaques generated, while antibody positive samples show a reduction in the number of plaques indicating
the presence of virus neutralizing antibodies. This test is very technically demanding, time-to-result may
be two weeks for DENV, and results can be impacted by infection status of the individual (primary versus
secondary and beyond). There may also be cross-reaction with antibodies within the DENV group as well
as other flaviviruses. Finally, even when performed correctly, the results of the SNPR between
laboratories may vary due to a lack of standardization, as protocols tend to be generated and modified inhouse. (Thomas et al., 2009)
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Flaviviruses exhibit a great deal of cross-reactivity in traditional serological assays (Petersen and
Barrett, 2009; Perera et al., 2008; Seligman, 2008; Calisher et al. 1989) hampering diagnostic efforts
where multiple viruses co-circulate. While serotyping dengue virus isolates may not be a priority when
using serological assays such as ELISA for diagnosis, ruling out neurotropic flaviviruses such as JEV,
SLEV, and WNV would be desirable. The explosive appearance of the potentially cross-reactive ZIKV
has only served to reinforce this point (Landry and St. George, 2017). There are two ways to describe
this cross-reactivity; the first is due to actual genetic conservation among the group and subsequent
expression in viral proteins. This conservation ultimately leads to the generation of truly cross-reactive
antibodies in humans upon infection. On the other hand, highly virus species-specific antibodies are also
generated during human infections and these are the most effective at neutralizing virus.
The second way to describe serological cross-reactivity is as an artifact of the assays used to
detect flaviviruses. To abrogate this obstacle in diagnostics, an approach that seems to have been
borrowed from the design of primers for use in polymerase-chain reaction has been recently employed.
Advances in the field have led to the development of novel peptides that are virus species-specific and
can either detect virus directly or the antibodies generated against them. Thus, cross-reactivity is
evidenced in serological analysis of flaviviruses due to antibodies that are generated against highly
conserved epitopes. Yet, cross-reactivity is not a necessary component of diagnostic assays; rather it is
a by-product of using complete antigens and/or polyclonal, cross-reactive antibodies rather than speciesspecific antigens and/or antibodies (i.e. monoclonal). This fact has been addressed and exploited in
newer ELISAs such as those directed at both DENV env and NS1, where serotyping has also become
possible thanks to the creation of serotype-specific monoclonal antibodies. (Ding et al, 2011; Midgley et
al, 2011; Castro-Jorge et al., 2010) Other methods of laboratory diagnosis, such as virus isolation and
traditional antigen detection, have even greater drawbacks such as length to result and undesirable
sampling requirements (Figs. 1.9 and 1.10).
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1.1.3.9.1.2. Histological Methods of DENV Diagnosis

Histological preparations may be used under the greater umbrella of DENV diagnostics such as
where material is obtained at autopsy from fatal cases. Histological changes have and will continue to
contribute to gaining a greater understanding of DENV pathogenesis but requires special circumstances
and a high degree of expertise. These samples are also amenable to immunohistochemical techniques
where the targeted detection of host and viral markers may be obtained, for instance, by fluorescent
staining. However, given the conditions required above in addition to the other diagnostic assays
available, collectively these methods are rarely used. (Petersen and Barrett, 2009)

1.1.3.9.1.3. Virus Isolation of DENV via Culture

Culturing DENV from patient samples is considered the ultimate gold standard in diagnostics as
with all infectious etiologies. This requires viral replication in susceptible cells whether they be primary,
such as PBMCs, or continuous cell lines, such as VERO (African green monkey, Cercopithecus aethiops
– kidney, epithelial) and C636 (mosquito, Aedes albopictus-larva) lines. Cytopathic effect (CPE) is often,
but may not always be evident in culture systems, however, indirect downstream methods are often used
to confirm infection. These methods to detect the presence of DENV are multifarious and include virus
plaque assay, detection of the viral genome by RT-PCR (now often via fluorescent signals in real-time
RT-PCR), and the detection of viral proteins by immunofluorescent assays. Production of disease in an
in vivo model after recovery of virus establishes a direct etiological relationship. A diagnostic assay then
may either measure the presence of virus directly (genome or protein detection) or indirectly (a marker of
host response such as specific immunoglobulin production against the virus). Finally, within these assays
these markers may be either measured directly (CPE, electron microscopy) or indirectly (colormetric or
fluorescent changes). Growth of DENV in cultures may take longer than one week post inoculation.
Depending on the type of assay used for confirmation these tests only serve to add to the time until
diagnosis. Maintaining the viability of virus in collected samples is also more difficult to produce than
preserving viral RNA and proteins or host antibody. For these reasons, virus isolation is used far less
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than other diagnostic assays. Virus isolation may be of use where it is desired to obtain virus stocks of
circulating strains and for additional genetic and epidemiological studies. Isolates from these cultures
may then be subjected to downstream assays such as genomic sequencing. (Munoz-Jordan et al., 2013;
Leparc-Goffart et al., 2009; Petersen and Barrett, 2009)

1.1.3.9.1.4. Molecular Methods of DENV Diagnosis

The detection of DENV RNA in patient samples gained traction in the early 1990s and one of
these methods, a nested version of RT-PCR, may be used to provide cDNA for downstream partial
genome sequencing. This particular assay is capable of detecting DENV as group during the initial
amplification and further amplification allows serotyping of the isolate (Lanciotti et al., 1992). The utility of
real-time quantitative RT-PCR has led to a number of methods appearing within the literature. One of
these methods has been recently approved for diagnostic use in the US by the FDA. This method is
serotype-specific and is available either in a single-well, multiplex format or in a single analyte, multiple
well format (CDC, 2015).
The usefulness of RT-PCR in DENV diagnostics has enabled our diagnostic capabilities to move
even closer to disease onset and detect infection in more acute cases. These assays have also allowed
the laboratory to gain an easy way to serotype DENV in patient samples. While the use of RT-PCR has
proven superior in many aspects with regards to DENV diagnostics, it has historically been both
prohibitively expensive and prone to process issues. Regarding expense, samples first require isolation
of nucleic acids adding to both labor and reagent costs. Second, the progressive advancements made
from end-point to real-time qRT-PCR have, while reducing time-to-result, added greatly to cost in both
platform (hardware and software) as well as reagents. RT-PCR assays, especially real-time platforms,
have proven prone to contamination, as these assays are dependent on the exponential amplification of a
target, in addition to other process related concerns such as inhibitory factors and sample degradation.
Genomic sequencing of isolates, whether partial or full-length, has also proven useful and enlightening
but play more of a role in epidemiology than diagnostics. (Munoz-Jordan et al., 2013; Leparc-Goffart et
al., 2009; WHO, 2009; Petersen and Barrett, 2009; Altshuler, 2006)
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Fig. 1.9: Direct and indirect methods for laboratory confirmation of DENV infection. The direct
methods for laboratory confirmation of dengue include detection of the virus either in whole (virus
isolation) or in part (genomic detection, NS1 detection) while indirect methods include serological assays
detectiong antibody to DENV (IgM, IgG). The direct methods of detection are more reliable but less
accessible and indirect methods, vice versa. (WHO, 2009)

Fig. 1.10: Summary of operating characteristics and comparative costs of dengue diagnostic
methods. Thisfigure illustrates the methods available to the clinical laboratory for use in DENV
diagnostics. Here, the pros an cons of each method are listed including (from left to right): whether an
assay is considered confirmatory for diagnosis of DENV infection, the approximate time to result for a
given assay, specimen type required, when such a sample should be obtained, facilities required, and
relative cost. An ideal assay would minimize the latter five criteria while remaining confirmatory. (WHO,
2009)
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1.1.3.10. A Novel Method for DENV Diagnosis and Prognosis - Microsphere-based Immunoassay (MIA)

The microsphere immunoassay (MIA) and the LuminexTM platform are based on the merging of
ELISA and flow cytometry laboratory assays. The first part of the assay involves the coupling of a
capture molecule such as a protein antigen or short nucleotide sequence to a polystyrene microsphere.
A target molecule within the sample then is captured and sandwiched with a detection molecule, and then
subsequently labeled with streptavidin-PE. The second part of the assay is based on the specific
wavelengths of two distinct lasers within the optical system of the platform. One laser is capable of
reading a signal from streptavidin-PE, while the other is capable of identifying up to 100 distinct bead sets
based on the ratio of two dyes contained within the beads. (Bio-Rad, 2010)
Regarding arboviral infections, the assay saw previous use in the serological detection of antiWNV IgG and IgM antibodies in the presence of serum. The emergence of WNV in the Western
Hemisphere led to the exploration of this platform as a potential advancement within current serological
diagnostic and surveillance methods, and in this regard the CDC has approved its use (Johnson et al.,
2007; Johnson et al., 2005). However, the assay is capable of detecting any number of serological
markers provided that a method of capture and detection has been developed. In fact, this ability has led
to the investigational use of the MIA not only in detecting WNV but additional arboviruses (Basile et al.,
2013; Basile et al., 2010). The FLDOH-BPHL-Tampa was in the process of attempting to develop a
single-well multiplexed assay capable of detecting antibody to WNV, SLEV, and eastern equine
encephalitis virus, primarily for arboviral surveillance in sentinel chicken serum (Stark, personal comm.).
The ability to multiplex has additionally led to the exploitation of the platform to detect both quantities of
host-derived markers of infections such as chemokines and cytokines as well as virus specific markers
(deOliveira-Pinto, et al., 2012; Gupta et al;, 2012; Thayan et al., 2010; Azizan et al., 2006; NE Reis et al.,
2007; Shmitt et al., 2006). This, in turn, allows for the assay’s usefulness to be expanded in its diagnostic
capability as it now may be developed to detect both active and past infections. The ability to multiplex
for target detection within the same well, on a level most diagnostic assays currently lack, only further
enhances the flexibility and usefulness of the platform.
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In order to have impact at the clinical level under this definition, the assay must be targeted at
patients still in the early phases of disease, this likely rules-out the use of DENV antibody as a useful
marker of infection in most cases (WHO, 2009). It has been recently suggested that the DENV
nonstructural protein, NS1 may be useful in this regard, and an NS1 assay by ELISA is available from
both Alere Inc. (Pan-Bio® Dengue Early ELISA #E-DEN02P) and Bio-Rad Laboratories, Inc. (Platelia
Dengue NS1 EIA #72830). DENV NS1 is secreted from infected cells to detectable levels in serum as
one of the earliest markers of infection and may persist into convalescence. It is a generally conserved
protein among flaviviruses but has been found to contain both cross-reactive and serotype-specific
epitopes among dengue viruses (Ding et al., 2011; Hu et al., 2011; Qiu et al., 2009; Xu et al., 2006;
Falconar et al., 1994; Falconar and Young, 1991; Mason et al., 1990). In a report by Alcon et al., 2002
(French Guiana) where an ELISA using polyclonal antibodies directed againt DENV NS1 was used, NS1
detection was possible between days 1-9 of onset, may occur without detection of viral RNA and/or IgM,
and showed no significant differences between primary and non-primary infections. The range of NS1
detection was 0.01-50μg/mL.
In 2006, the Platelia™ Dengue NS1 Ag microplate EIA (Bio-Rad, Hercules, CA) was used in the
screening of 80,000 Puerto Rican blood donors. At the time of the FDA approval for the study, the test
was already in use in approximately 40 countries around the world (Bio-Rad, 2010). Reports of the
investigational use of commercially available DENV NS1 diagnotic assays in Brazil (Castro-Jorge et al.,
2010) and Malaysia (Wang and Sekaran, 2010) showed favorable results when compared against
traditional serological and virological methods with sensitivities of 95.9 and 76.76% and specificities of
81.1 and 98.31%, respectively. The former group used the Platelia™ Dengue NS1 EIA (Bio-Rad,
Hercules, CA) and the latter, the SD Bioline Dengue Duo (Standard Diagnostics, Yongin-si, Rep. Korea).
During the 2012-13 dengue epidemic in French Guiana, 3,347 suspected cases were subjected to both
the Platelia™ and SD Bioline assays where the Platelia™ assay and RT-PCR were considered standard
assays. The SD Bioline compared very favorably to both standards where it detected NS1 in 471
samples (14.1%) and the Platelia™ assay identified 14.2% samples as positive. The sensitivity and
specificity of the SD Bioline assay were 87 and 92% respectively when compared to RT-PCR (Simmonet
et al., 2017). In d.R.Q. Lima et al., 2010, two of the previously mentioned assays, the PanBio® ELISA
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and the Platelia™ EIA, were compared against another immunoassay, the Dengue NS1 STRIP (Bio-Rad,
Hercules, CA). The STRIP is an immunochromatographic test (ICT) similar to the previously mentioned
SD Bioline Dengue Duo. While all obtained specificities near 100%, here they found the STRIP assay to
have the highest sensitivity (89.6%), followed by the Platelia™ EIA at 83.6%, and the Pan-Bio® ELISA at
72.3%. However, concerns of the sensitivity of the Platelia™ assay arose in a study in Aracaju, Brazil
where 58 of 119 EIA negative samples were later found to actually be DEN4 positive by confirmatory
tests, alluding to an issue with the detection of secondary cases (Faria Sea et al., 2013). A subsequent
report indicates that this drawback can be alleviated by heat-treating samples at 100°C for 5 minutes
(d.R.Q. Lima et al., 2014). Previously in 2003, Koraka et al. developed a dot blot assay to detect DENV
NS1 and found that acid treatment to release immune-complexed NS1 increased detection from 22/55 to
43/55 in their samples (compared to 32/55 in RT-PCR) additionally alluding to concerns with appropriate
sample treatment prior to assaying. Gaikwad et al., 2017 took a similar approach to those detailed above
in comparing a DENV NS1 ICT (Bhat BioScan Rapid Dengue NS1 Antigen, Bhat BioTech, Karnataka,
India), DENV NS1 ELISA (RecombiELISA, CTK Biotech, San Diego, CA), and RT-PCR (here real-time).
Compared to RT-PCR, the rapid ICT showed a sensitivity of 81.5% and specificity of 66.7% (concordance
of 75.5%), whereas the ELISA showed a sensitivity of 89.9% and specificity of 100% (concordance of
94%). Another group (Mata et al., 2017) was interested in the effectiveness of using an ICT (BioEasy™
Dengue Eden Test, Standard Diagnostics, Yongin-si, Rep. Korea) in detecting DENV NS1 in whole-blood,
point of care samples. In 120 positive dengue samples (combined RT-PCR and Platelia™ standards) this
assay showed a sensitivity of 76.7% and specificity of 87% when read at 15m. Here, they also note that
invalid results read at 15m should be read at 30m and that both sensitivity and specificity of the assay
were higher for sera (82.2% and 100%). Additionally, DENV NS1 ELISAs derived from monoclonal
antibody libraries capable of serotyping dengue virus NS1 in patient samples are under development,
such as those reported in Austalia, via biopanning/phage-display (Lebani et al., 2017), as well as in China
(Ding et al., 2011; Hu et al., 2011; Qiu et al., 2009; Xu et al., 2006) and Thailand (Puttikhunt et al., 2011).
In all, these types of assays may represent the new paradigm for DENV diagnostics in many parts of the
world.
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It has also been well established that severe DENV illness is correlated with elevated levels of
certain cytokines, chemokines, and other host-derived molecular markers in patient serum. For an assay
to be of prognostic value, these host markers must be measurable in a significantly consistent yet
differential pattern at an appropriate time during clinical presentation. A huge body of work has been
compiled already, mainly in cell culture and mouse models of DENV infection, but a complete picture still
remains elusive. Part of the problem stems from the lack of a true animal model for studying dengue and
the difficulty with obtaining human serum/CSF samples for analysis. Regardless, a number of host
markers, especially those that are pro-inflammatory in nature, may be useful for differentiating severity of
dengue illness prior to development. IFN-α, IFN-γ, TNF-α, IL-2, 4, 6, 8, 10, 12, sIL-2R, macrophage
migration inhibitory factor, CCL2/MCP-1, CXCL10/IP-10, IL-1β, elastase, sTNFR, RANTES, MIP-1α, MIP1β, IL-1ra, sICAM-1, sVCAM-1, and VEGF have all been investigated and implicated as being elevated in
DENV infections in one form or another. (Appanna et al., 2014; Rathakrishnan et al., 2014; deOliveiraPinto, et al., 2012; Gupta et al;, 2012; Puerta-Guardo et al., 2012; Thayan et al., 2010; Azizan et al.,
2009; Sun et al., 2009; Basu and Chaturvedi, 2008; Boonnak et al., 2008; Chen et al., 2008; Restrepo et
al., 2008; Yen et al., 2008; Azizan et al., 2006; Halstead, 2007; Dong et al., 2007; NE Reis et al., 2007;
Azizan et al., 2006; Fink et al., 2006; Shmitt et al., 2006 Shresta et al., 2006; Lin et al., 2005; Mangada
and Rothman, 2005; Avila-Aguero et al., 2004; Dewi et al., 2004; Bosch et al., 2002; Suharti et al., 2002).
Individual results are sometimes in direct conflict with other reports, paradoxically, given generally
accepted, specific roles of these effector molecules in addition to the overarching model of DENV
pathogenesis. This serves to point to the complexity in assessing serum markers for potential disease
severity.

1.2. Statement of the Problem

Dengue is a problematic disease to manage at the clinical level. Until recently, the laboratory’s
capacity for diagnosing infections with DENV has been left wanting in many respects. Before any
advances can be achieved regarding treatment, diagnostic methods capable of detecting disease at the
earliest onset of symptoms are mandatory. Ideal diagnostic tools are sensitive, specific, fast, user-
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friendly, and inexpensive. Diagnostic methods currently in use fulfill some, but not all, of these criteria. In
cases where the disease is endemic and clinics are over-burdened with ill patients, a prognostic assay
capable of allowing the proper management (triage) of patients is desired. Clinicians still rely upon
traditional techniques when issuing prognoses where multiple tests may be requested using different
techniques and equipment in order to establish a patient’s risk of developing severe illness. This, in turn,
taxes the already burdened health-care system and many patients that should be otherwise sent home
are monitored unnecessarily. The development of an assay that can, in concert, diagnose infection with
DENV and be of prognostic value could alleviate this burden. Recent advancements in the understanding
of the clinical profiles of DENV-infected patients at the molecular level gives reason for hope. The MIA
offers the possibility for achieving the task of concomitantly combining diagnostic capabilities via DENV
NS1 detection with measuring host-derived markers capable of differentiating patients that will manifest
uncomplicated dengue from those that will develop severe illness. This assay would be required to:
(1) diagnose infections by dengue virus with high sensitivity
(2) rule-out other infectious etiologies with high specificity
(3) have rapid turn-around time to result, ideally <24h after sample collection
(4) be cost-effective to those health-care systems that require it
(5) be capable of differentiating those patients that will progress to severe illness from those with
uncomplicated dengue
Therefore, with the availability of the MIA platform to assess up to 100 different markers within the
same well, it has the potential for becoming one of the most useful assays in the management of dengue
patients. Determining which markers to include as a measure of potential disease severity at a time
commensurate with patient presentation is a priority with respect to triage. Inclusion of a diagnostic
marker indicative of DENV infection, here DENV NS1, is mandatory. This assay would simplify current
patient care algorithms and reduce the workload at the clinical level as management of the patient would
require only a single laboratory test in addition to the discretion of the attending physician. This study
attempted to investigate the feasibility of such an approach.
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1.3. Specific Aims

1. Evaluate cytokine production in DENV-infected HPMEC ST1.6R (endothelial) and u937
(monocyte) cell cultures and human sera using a 27-plex MIA cytokine assay.

2. Select relevant cytokines/chemokines for further analysis in MIA using DENV-infected
human sera.

3. Evaluate monoclonal antibodies directed against DENV NS1 protein for use in MIA.

4. Use appropriate mAbs for detection of DENV NS1 in DENV-infected cell cultures and
human sera via MIA.

5. Compare results of DENV NS1 MIA to a commercially available DENV NS1 ELISA.
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CHAPTER 2. DETECTION AND QUANTIFICATION OF SELECT CYTOKINES AND CHEMOKINES
PRODUCED IN IN VITRO MODELS OF DENV INFECTION VIA MIA

2.1. Introduction

As discussed in Chapter 1 (1.1.5.8.), several different types of cells are thought to play an
important role in DENV pathogenesis. Monocytes and macrophages are thought to be targets of
infection, especially during secondary (non-primary) infection, where they uptake non-neutralized virus
when presented by professional antigen-presenting cells (APCs) and where antibody-dependent
enhancement (ADE) of infection is thought to occur (Boonak et al., 2010; Honda et al., 2009; Boonak et
al., 2008; Chen et al., 2008; Fink et al., 2006; Huang et al., 2006; Kontny et al., 1988). They additionally
serve as potent immune effector cells during infection via production of numerous cytokines and
chemokines either directly or via signaling cascades. Endothelial cells (ECs) within the vasculature are
responsible for inducing plasma leakage that is a hallmark of DENV infection, especially during severe
illness, either via direct damage, indirect damage, or the relaxation of gap junctions (Appanna et al.,
2014; Azizan et al., 2009; Azizan et al., 2006; Peyrefitte et al., 2006; Dewi et al., 2004). Therefore, in
vitro models that include cell lines derived from either type of cell have proven useful for studying certain
aspects of DENV pathogenesis. In this study two cell lines, HPMEC ST1.6R (derived from human
microvascular pulmonary endothelial cells) (Unger et al., 2002) and u937 (derived from human
monocytes) (Sundstrom and Nilsson, 1976) were investigated for reasons that included ascertaining
permissiveness of DENV infectivity and the resultant response of host markers to inoculation with DENV.
The ultimate goal here was to obtain data that would be useful in developing immunological profiles and
to supplement data that would be gathered from human sera as detailed in Chapter 3, in order to identify
prognostic markers differentiating outcomes of DENV infection.
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2.2. Studies in HPMEC ST1.6R Cell Line

2.2.1. Infection of DEN1 and DEN3 in HPMEC ST1.6R Cell Line, Confirmation of Infection via qRTPCR, and Investigational Detection of DENV NS1 via ELISA

2.2.1.1. Methods

HPMEC ST1.6R cells were grown to 80-90% confluence in 6-well culture plates (BectonDickinson, East Rutherford, NJ, #3533934), overlaid with endothelial cell basal medium (EBM, Lonza,
Basel, Switzerland, cat. CC-3121), and supplemented with endothelial cell growth medium (EGM
SingleQuotTM, Lonza, cat. CC-4133) on a substrate of 0.2% gelatin. Prior to inoculation, the cell culture
medium was aspirated and the monolayer washed with HEPES. Volumes of 100uL of DEN1 and DEN3
(Table 2.1) at stock concentrations (1.025x107 and 6.666x106 pfu/500μL, respectively) were inoculated
onto the monolayer in duplicate along with mock (uninfected C636 cell culture supernatant) and control
(EGM complete) wells in duplicate (i.e. one well, two plates) for each time point, control media were not
included in 27-plex MIA. The plates were then incubated for two hours at 37°C, 5% CO 2 while being
periodically rocked. After incubation, the inoculum was aspirated, the monolayer washed using EBSS,
and 3mL EGM (supplemented EBM) added. Duplicate plates corresponding to time points 0, 2, 8, 24, 48,
96, 144, and 196h post-infection (p.i.) were then sealed and frozen at -70°C for later analysis via MIA,
SYBR Green qRT-PCR, and investigational DENV NS1 detection via ELISA (the latter-most excluded
samples at 2h and 8h). For the DENV NS1 ELISA (Inverness Medical, PanBio, Sinnamon Park,
Queensland, Austalia, #E-DEN02P), DEN2-, DEN4-, WNV- (NY99), and SLEV- (TBH28) infected HPMEC
ST1.6R samples were also included, from time points 0, 24, 48, 96, and 144h p.i. and diluted 1:2 with kit
diluent (75μL/75μL) immediately prior to addition in ELISA. The DENV NS1 ELISA was then performed
according to manufacturer’s instructions. Index values for each sample were obtained first by dividing the
absorbance values of each sample by the assay cut-off value. The cut-off value was obtained by
multiplying the average absorbance values of the calibrators by the assay calibration factor. Index values
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<0.9 were interpreted as negative for DENV NS1 detection, between 0.9 and 1.1 as equivocal, and >1.1
as positive results.

Table 2.1: Strains and titers of DENV1-4 used in for inoculating HPMEC ST1.6R and u937 cell-lines.
Serotype
Strain
Titer (pfu) 500μL
DEN1
Mochizuki Hawaii 1944
1.025x107
DEN2
New Guinea C
1.450x107
DEN3
H87 Philippines 1956
6.666x106
DEN4
H-241P Philippines 1956
8.000x106
2.2.1.2. Results

RNA detection of DEN1 and DEN3 of samples obtained from HPMEC supported only a low-level
infection of HPMEC by DEN3 (Fig. 2.1) where all CT values obtained were approximately=30. The C T
values obtained for DEN1-infected HPMEC were practically identical to those of mock-infected cultures at
each time point, (appx.= 40) and taken as false positive results. The SYBR Green qRT-PCR that was in
use during this stage of the study is especially prone to false positive signals at the extreme end of runs
(Shu et al., 2003). Regarding DENV NS1 detection in HPMEC ST1.6R cultures, all DENV1-4 samples (at
all time points p.i.) were positive as determined by ELISA (Table 2.1). Additionally, all negative control
samples as well as all WNV- and SLEV-infected HPMEC cultures (at all time points) were found to be
negative by ELISA. Interestingly, all DEN3 samples after 0h were found to have noticeably lower positive
index values than those of the other three DENV serotypes.
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Table 2.2: DENV NS1 detection via ELISA for DENV1-4-, WNV-, and SLEV-infected cell cultures of
HPMEC ST1.6R cell line in addition to uninfected cell control cultures at selected time points postinoculation (p.i.). DENV NS1 detection via ELISA was performed on DENV1-4-, WNV-, SLEV-, and
mock-infected HPMEC cultures for samples taken at time points 0, 24, 48, 96, and 144h p.i. Note that all
four DENV serotypes were positive for detection of NS1 at all time points whereas all samples at all time
points for WNV, SLEV, and mock-infected controls were negative. Index values represent average
absobance values of samples divided by the cut-off value. Samples with index values < 0.9 are negative,
between 0.9 and 1.1 equivocal, and > 1.1 positive for DENV NS1 detection.
Sample
Index value Result
Sample
Index value Result
WNV 0h
0.30
Negative
DEN4 24h
6.60
Positive
WNV 24h
0.53
Negative
Control 24h
0.15
Negative
WNV 48h
0.87
Negative
DEN1 48h
6.56
Positive
WNV 96h
0.46
Negative
DEN2 48h
6.62
Positive
WNV 144h
0.87
Negative
DEN3 48h
5.41
Positive
SLEV 0h
0.71
Negative
DEN4 48h
6.57
Positive
SLEV 24h
0.25
Negative
Control 48h
0.20
Negative
SLEV 48h
0.34
Negative
DEN1 96h
6.40
Positive
SLEV 96h
0.41
Negative
DEN2 96h
6.47
Positive
SLEV 144h
0.33
Negative
DEN3 96h
4.22
Positive
DEN1 0h
5.91
Positive
DEN4 96h
6.38
Positive
DEN2 0h
6.60
Positive
Control 96h
0.70
Negative
DEN3 0h
5.20
Positive
DEN1 144h
6.62
Positive
DEN4 0h
6.55
Positive
DEN2 144h
6.60
Positive
Control 0h
0.22
Negative
DEN3 144h
3.88
Positive
DEN1 24h
6.53
Positive
DEN4 144h
5.37
Positive
DEN2 24h
6.60
Positive
Control 144h
0.26
Negative
DEN3 24h
1.84
Positive
HPMEC 1:2 (sample:kit diluent)

Fig. 2.1: RNA detection in DEN1, DEN3, and mock-infected HPMEC ST1.6R cell cultures via SYBR
Green qRT-PCR at selected time points. The above figure illustrates CT values obtained by SYBR
Green-based qRT-PCR for DEN1, -3, and mock-infected HPMEC ST1.6R cell cultures at time points 0, 2,
8, 24, 48, 96, 144, and 192h post-inoculation (p.i.). Note that C T values obtained for DEN3 tends to
indicate a low-level detection of viral RNA/infection while the values for DEN1 tend to parallel those of
mock-infected cultures indicating that a productive infection was not established. Plotted C T values
represent averages of triplicate wells. Uninfected controls were not included in qRT-PCR analysis.
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2.2.2. Cytokine and Chemokine Analysis of DEN1- and DEN3-infected HPMEC ST1.6R Cell-line via
27-plex MIA

2.2.2.1. Methods

As stated above, duplicate plates containing DEN1-, DEN3-, and mock-infected HPMEC cell
cultures were frozen at -70°C at time points 0, 2, 8, 24, 48, 96, 144, and 192h p.i. Upon preparation for
qRT-PCR and 27-plex MIA analysis, these cultures were thawed and aliquots containing enough sample
for each assay were collected. At this point, a modified version of the manufacturer’s instructions were
followed for the Bio-Plex Pro™ human cytokine 27-plex assay, (Bio-Rad #M500KCAF0Y) as outlined in
the Bio-Plex Pro™ Assays: Cytokine, Chemokine, and Growth Factors Instuction Manual (Bio-Rad,
Hercules, CA). The target analytes for this assay can be found in Table 2.2. The modification of this
protocol occurred with a UV inactivation step after clarification of samples by centrifugation. For this UV
inactivation step, each sample was added to an individual well of a sterile 96-well flat bottom plate
containing enough volume for two reactions in MIA. These samples were then subjected to 10min UV
exposure, the plate covered, subsequently wrapped in foil, and placed in a refrigerator at 4°C until
samples were ready for use.

Table 2.3: Cytokine and chemokine target analytes of commercially available 27-plex MIA.
27-plex MIA cytokine kit (target analytes):
IL-1β
IL-8
IL-1ra
IL-9
IL-2
IL-10
IL-4
IL-12(p70)
IL-5
IL-13
IL-6
IL-15
IL-7
IL-17

Eotaxin
Basic FGF
G-CSF
GM-CSF
IFN-γ
IP-10
MCP-1

MIP-1α
MIP-1β
PDGF-BB
RANTES
TNF-α
VEGF

2.2.2.2. Results

Here, only 11 of the 27 analytes measured in the assay produced observable responses, 5 of
which were later included in a 5-plex assay analyzing human sera (IFN-γ, IL-10, IP-10, GM-CSF, and
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MCP-1) per our specific aims. Results that were of interest included profiles for IL-6, IL-8, VEGF, and
MCP-1. Concentrations detected for IL-6 (Fig. 2.2 – top left) showed a peak at 2h, a subsequent waning
until 48h, followed by a gradual increase in detection all the way through 192h for both DEN1 and DEN3
but not mock-infected HPMEC. Concentrations of IL-8 (Fig. 2.2 – top right) in DEN3-infected HPMEC
were interesting for the fact that results were above the observable range of detection beginning at 96h.
DEN1-, DEN3-, and mock-infected concentrations of VEGF in HPMEC (Fig. 2.2 – bottom left) all showed
a similar profile until elevation occured in DEN3 beginning at 96h through 192h. Interestingly [VEGF] in
both DEN1- and mock-infected cultures were practically identical until 192h when concentrations in DEN1
inoculated HPMEC rose to levels near those found for DEN3 (2478.38 versus 2587.79pg/mL,
mock=1028.68pg/mL). Results for [MCP-1] in DEN1 and DEN3 (Fig. 2.2 – bottom right) showed similar
profiles to those for IL-6, where an initial increase in detection at 2h was observed, followed by a waning
until 24h, followed, here, by a more marked increase through 192h. The differences here though, were
first, that concentrations of MCP-1 were nearly identical between serotypes until 24h and a marked
increase in detection in DEN3 compared to DEN1 was only observed beginning at 48h. Additionally,
unlike [IL-6] in mock-infected HPMEC where no, or nearly no, detection occurred over the course of
infection, [MCP-1] in these cultures were found at elevated concentrations lying between those of DEN3
and DEN1 at 96h, 144h, and 192h.
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Fig. 2.2: Concentrations of IL-6, IL-8, VEGF, and MCP-1 (pg/mL) produced in either DEN1-, DEN3-, or mock-infected HPMEC ST1.6R cellline at selected time points as determined by 27-plex MIA. The above figure illustrates the concentrations of IL-6 (top-left), IL-8 (top-right),
VEGF (bottom-left), and MCP-1 (bottom-right) (pg/mL) as determined by 27-plex MIA for DEN1- (blue-diamond), DEN3- (orange-square), and
mock-infected (gray-triangle) HPMEC ST1.6R cell cultures. These concentrations were measured for samples obtained at 0, 2, 8, 24, 48, 96, 144,
and 192h post-inoculation (p.i.). Concentrations of IL-6 for each DEN1 and DEN3 showed a sharp peak at 2h, followed by waning in detection
until 48h, and a gradual increase through 192h. IL-8 concentrations were above the observable range of the assay after 48h. DEN1 [VEGF] were
nearly identical to those of mock-infected cultures until 192h when detection nearly matched that of DEN3. Concentrations of MCP-1 showed a
similar profile to that of IL-6 but with a more dramatic increase through 192h. Each dot represents the average concentrations of individual
samples ran in duplicate wells (DEN1 and-3) or single wells (mock).
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2.2.3. Discussion

While endothelial cells of the vasculature are known to play an important role in the pathogenesis
of dengue illness, their direct role in dengue virus infections remains unclear (Dewi et al., 2004). Certain
models maintain that they are either not permissive to infection or play a largely indirect, but important
role in pathogenesis, such as releasing immune effector molecules and reactions to DENV NS1 that
cause either apoptosis or an increase in vascular permeability (Basu and Chaturvedi, 2008; Pang et al.,
2007; Green et al., 2006; Lee et al., 2006; Lin et al., 2005). Other models posit that infection of ECs with
DENV plays a direct role in vascular leakage (Azizan et al., 2009; Azizan et al., 2006; Appanna et al.,
2014; Ochoa, et al., 2009) and that direct infection can induce both production of IL-6 and IL-8 (Huang et
al., 2000). In either case, all four of the analytes of interest here, IL-6, IL-8, VEGF, and MCP-1 have been
found to play a role in response to DENV in ECs. The results of this in vitro study point to, at the very
least, a degree of permissiveness to infection when comparing the qRT-PCR results of DEN1 versus
DEN3 inoculated HPMEC cell cultures. It was our conclusion that no viral RNA was detected at any time
point for DEN1-infected cultures while a moderate amount of viral RNA was detected at all time points for
DEN3-infected cultures. As far as the investigational use of the DENV NS1 ELISA, the results here
provided for some encouraging results. The fact that only DENV1-4-infected HPMEC samples were
positive for NS1 detection would seem to rule out any cross-reactivity with culture-dervied proteins in
addition to WNV and SLEV NS1. More in depth discussions of DENV NS1 assays such as this ELISA
occur in Chapters 1 (1.1.5.10.) and 4. Results of the in vitro study using u937 DENV1-4-infected cultures
were largely unacceptable and are not reported here with the following exceptions: similar attempts
should use an MOI of at least 10 instead of 1, should be paired with ADE models of infection in this cellline, and that treatment with DENV1-4 supported differential detection of RANTES, VEGF, and MCP-1 at
144h p.i. only.
It is important to note that the main purpose of performing 27-plex MIA screening here, was to
determine if differential detection of the analytes measured occurred in DENV-infected cell culture models
versus non-infected cultures, and if there were additional serotype-specific responses. The approach
used here would not reveal much in a mechanistic way beyond these average differences in addition to
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those that were time-dependent. This specific experiment provided useful results for only IL-6, IL-8,
VEGF, and MCP-1 that would support their further investigation in similar experiments, which was the
goal of using the screening approach described here. As stated above, each of these have been found to
be elevated in both ‘classic’ and severe models of DENV in vitro. It is also important for the sake of
developing immunological profiles that these results are also true in vivo such as elevated levels of IL-6
and IL-8 in DENV patients as reported in Avila-Aguero et al., 2004. Despite the methodological errors
that are discussed above, we can report some positive results for 27-plex MIA of DENV-infected HPMEC.
For instance, the results for IL-6, and to a lesser extent, MCP-1 exhibited the type of profiles that we were
interested in, where clear differences were seen between sample types, both at individual time points, in
addition to the duration of infection. If the results for [IL-8] could be reproduced, this would also be
extremely interesting regarding the targeting of this analyte for DENV immunological profiling. It would
also be valuable to determine where these values from 96h actually lie and this would require standards
that would allow measurement. The profile for VEGF, where concentrations are dramatically higher at
later time points also seems to support previous data. In all, this approach allows for the targeting of
specific analytes, which will then allow for additional replicates, providing for robust statistical analyses.
Although we were not primarily concerned with the biological reasons responsible for profiles in this
study, rather only establishing differences, it is very enticing that these profiles can map, over time, what
is happening in vivo and can serve to support the theories underpinning pathogenesis. For instance, it
would be interesting to determine that if the dramatic increase in IL-8, a proinflammatory cytokine, that is
seen here at around 96h in HPMEC is also seen in vivo, and if so, at what time during course of infection,
and what the outcome of such a response would be (i.e. resolution of illness versus development of
severe disease).
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CHAPTER 3. IMMUNOLOGICAL PROFILES OF HUMAN SERA AS DETERMINED BY
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3.1. Abstract

Objectives: This study attempted to utilize the microsphere-based immunoassay (MIA) in order to
ascertain immunological profiles of dengue virus (DENV)+ patient sera. It is hoped that developing
profiles will alleviate patient management concerns and inform prognoses.

Methods: Two distinct sets of sera previously assayed for DENV were subjected to MIA. The first was
assayed for 27 analytes and the second included 5 markers: GM-CSF, IFN-γ, IP-10, IL-10, and MCP-1.

Results: Four of 5 analytes (IFN-γ, IP-10, IL-10, MCP-1, but excluding GM-CSF) were observed at higher
average concentrations in DENV PCR+ patient sera than those in DENV+ sera by ELISA and healthy
individuals. Statistically significant differences were found for elevated levels of IL-10 in DENV PCR+
sera (p=0.035) and values for IP-10 (p=0.093) and MCP-1 (p=0.058) were of borderline significance. No
significant differences were found for IFN-γ (p=0.193) or GM-CSF (p=0.493). These results point towards
immunological profiles that may distinguish acutely ill DENV PCR+ patients from ELISA+ patients and
healthy individuals.

Conclusions: The MIA is a useful rapid assay capable of producing meaningful immunological profiles of
acutely ill DENV infected patients. To support the findings of this study, future studies should include
larger sample sizes in addition to acute sera from severe DENV cases.

Keywords: dengue, DENV, cytokine, microsphere, immunological profile, Luminex

3.2. Background

Infection with dengue virus continues to be a worldwide threat to public health both in human and
economic costs. In 2015, dengue is still the most significant arthropod-borne (arbo-) viral illness.
Worldwide, an estimated 390 million infections occur annually where most cases go unreported; for
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instance, in 2010 only 2.4 million cases were reported to WHO; where 96 million cases were actually
thought to present clinically and the vast majority of infected individuals never seek medical attention.
There is currently a global population of 3.9 billion at risk of acquiring dengue, according to WHO.
Approximately 500,000 of these patients will progress to severe illness and require hospitalization, and
around 2.5% of these cases will be fatal[1,2]. Additionally, in 2009-2010, dengue virus established its first
recorded endemic transmission cycle in the state of Florida in over a half century, first within the Florida
Keys during 2009-2010, followed by an additional, unrelated outbreak in Martin County in 2013 [3]. There
are four currently recognized serotypes of DENV and all four circulate in most endemic regions, whereas
both outbreaks in Florida were caused by serotype 1 dengue virus.
Dengue is caused by one of four different serotypes of small RNA viruses in the family
Flaviviridae, DENV1-4. The 5’ and 3’ ends of the DENV genome contain untranslated regions (UTRs)
that vary in size according to serotype. The DENV genome’s open reading frame encodes first, the three
structural proteins, C, prM/M, and env, followed by 7 non-structural proteins and is translated as a single
polyprotein that is processed and modified post-translationally[4]. The host response to dengue virus
infection plays a large role in determining the resultant severity of illness and a laboratory test capable of
predicting the course of illness would be of tremendous value to the clinic.
Lack of therapeutic treatment options coupled with a suitable vaccine on the market still not fully
realized continue to offer challenges in attempts at controlling dengue. This leaves proper clinical
management as the only option for reducing morbidity and mortality associated with cases of dengue.
Infection with dengue leads to three stages of illness; the acute febrile phase, the critical phase, and
finally followed by either recovery or worsening to severe illness. Severe illness may include any or all of
the following: hemorrhage, shock, and/or death, but exhibits the common feature of plasma leakage due
to an increase in vascular permeability. The febrile phase begins abruptly from 2-7 days after infection
with non-specific symptoms. Most often, when patients present at the clinical level during this phase,
those who may progress to severe illness and those that will experience uncomplicated illness are
indistinguishable. The beginning of the critical phase usually coincides with defervescence on days 3-7 of
illness, and lasts 24-48 hours. It is at this stage where ‘warning signs’ for development of severe illness
often become apparent and certain patient criteria are evaluated for admitting and managing patients,
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ranging from presence of fever to evidence of plasma leakage. At any stage prior to this, a laboratory
assay that is able to identify and distinguish patients according to severity would be of tremendous
value[5].
Clinicians still rely upon clinical and laboratory techniques such as measuring hematocrit and liver
enzyme levels, in addition to evidence of pleural effusion, thrombocytopenia, petechiae, and/or
hemorrhage, when determining patient prognoses. In a recent longitudinal study examining 504 patients
with dengue-like symptoms, a number of these clinical findings were suitable for monitoring disease
progression over time but unable to distinguish patients early during presentation[6]. It can be argued
therefore, that clinicians lack an expedient platform for triaging patients with the greatest potential to
develop severe illness. This, in turn taxes the already burdened health-care system; for instance, simply
via the number of personnel that are required to interact with a single DENV patient. Also, many patients
that should be otherwise sent home may be monitored unnecessarily.
Regarding the immune response of a given individual, the generation of normally beneficial
inflammatory mediators in quantities that become damaging is generally thought to be a predominant
mechanism involved with severe dengue pathology. This generation of a ‘cytokine storm’ is thought to be
the ultimate factor in those that progress to severe illness. While it has been well established that severe
DENV illness is correlated with elevated levels of certain cytokines, chemokines, and other host-derived
molecular markers in patient serum, determining temporal profiles of these markers remains a key to
informing prognoses. For an assay to be of prognostic value, these host markers must be measurable in
a significant and consistent yet differential pattern at an appropriate time during clinical presentation when
considering outcomes. While the sequence of cascades and the exact players involved have yet to be
fully elucidated, TNF-α and IFN-γ seem to be two of the most important mediators and are often found to
be elevated in severe illness

[7,8].

Additionally, interleukins (ILs)-1β, 2, 4, 6, 8, 10, 12, macrophage

migration inhibitory factor, granulocyte-monocyte colony stimulating factor (GM-CSF), monocyte
chemoattractant protein (MCP)-1 or CCL2, elastase, regulated and activated upon normal transcription
expressed and secreted (RANTES), macrophage inflammatory protein (MIP)-1α, MIP-1β, interferon-γ
inducible protein (IP)-10 or CXCL10, soluble intercellular adhesion molecule (sICAM-1), soluble vascular
cell adhesion molecule (sVCAM)-1, and vascular endothelial growth factor (VEGF) have all been
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implicated to play a role in severe illness and more appropriately illustrate the ‘cytokine storm’[7-19].
However, individual results of studies are sometimes in direct conflict with other reports, given generally
accepted models of the specific roles of these effector molecules as well as that of DENV pathogenesis.
This serves to point to the complexity in assessing serum markers for predicting potential disease
severity. Given the sheer number of cytokines, chemokines, and host-derived growth factors, and their
myriad pathways as reported in the literature for dengue infections, the goal of identifying useful
immunological profiles is certainly a daunting task. However, it is believed that a suitable minimum
number of markers should become apparent that would allow for identifying immunological profiles
capable of predicting the severity of illness in patients.
Determining immunological profiles would be most useful in locales where the disease is endemic
and clinics are over-burdened with dengue patients. Here, a prognostic assay capable of allowing a more
expedient method for the triage and proper management of retained patients is desired. As a platform
capable of measuring multiple analytes representative of this ‘cytokine storm’, the microsphere
immunoassay (MIA) and the LuminexTM platform may be useful in identifying host immune factors
affected in response to infection by dengue virus. This information would be useful in developing
immunological profiles of dengue patients that encompass the entire spectrum of clinical illness [20].
Therefore, the MIA has the potential of becoming one of the most useful assays in the
management of dengue patients. Determining which markers to include as a measure of potential
disease severity at a time commensurate with patient presentation is a desirable goal with respect to
identifying dengue infected patients to triage and prioritize treatment. If a diagnostic marker indicative of
DENV infection could be included within this assay, its value should only increase. This would also
simplify current patient care algorithms and reduce the workload at the clinical level, as management of
the patient would require only a single laboratory test in addition to the discretion of the attending
physician. This study attempted to investigate the feasibility of such an approach; first by using a 27-plex
MIA to screen for potential markers in human sera followed by a targeted 5-plex MIA.
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3.3. Results and Discussion

3.3.1. Detection and Quantification of Select Cytokines and Chemokines Produced in vivo (DENV
Positive Patient Sera) via 27-plex MIA

A group of 38 serum samples fitting one of five clinical criteria (see Methods 3.5.3.1.) were
chosen for MIA analysis. The goal of using serum samples was to determine if the detection levels of the
27 analytes included for analysis (Table 3.1) resulted in observed profiles of differential detection for each
of the individual analytes among these subsets of samples. Here, 19 of 27 analytes produced observable
detection, including 4 of 5 analytes chosen for inclusion in a subsequent custom 5-plex assay, including
IL-10, IFN-γ, IP-10, and MCP-1 but not GM-CSF (Figs. 3.1a-1d). The five analytes mentioned above
were chosen for subsequent MIA analysis of sera, in part, due to the results of the 27-plex assay in
addition to those of unpublished data from our in vitro studies of DENV infection using MIA. This
unpublished data took into account the elevation of these markers in a temporal fashion as determined by
MIA in DENV infected monocyte and endothelial cell culture-based systems.
Five analytes were examined in detail for the presence of significant differences between sera
subsets. Neither IFN-γ [F(4,28)=0.51, p=0.729] nor MCP-1 [F(4,28)=0.09, p=0.985] analyte results
indicated that sample groups were distinct in the production of these host markers. The smallest pvalues, also lacking a statistically significant difference, were found for the IL-10 [F(4,28)=1.20, p=0.333]
and IP-10 [F(4,28)=1.29, p=0.298] analytes, where F is the ratio of the between groups to within groups
mean square for each test.
For the IL-10 analyte, each sera subset had multiple undetected analyte concentrations, i.e. zero
values, with all measurements below 50pg/mL. Interquartile ranges of the sample subsets were
determined for each analyte to denote the range of concentrations falling within the middle 50% of values
(calculated as the difference between the first and third quartiles). These are denoted by the shaded box
regions of Fig. 3.1a-d. Acute sera positive for DENV had the largest interquartile range (IQR=9.74pg/mL)
of all sera subsets for this analyte, including DENV negative sera (IQR=0.17pg/mL). The widest overall
range of concentrations (40.30pg/mL), as well as the greatest mean (μ=7.53pg/mL) and standard
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deviation (σ=13.56pg/mL), were also found in the acute DENV positive sera group. All subsets had
similar distributions and median values, ranging from 0pg/mL to 0.34pg/mL.
IFN-γ analyte concentrations were similar across all 5 sera subsets, with all concentrations under
150pg/mL and few zero values in any group. Interquartile ranges were comparable among sample
groups, with the widest (IQR=43.72pg/mL) and narrowest (IQR=17.41pg/mL) ranges calculated in DENV
negative and convalescent WNV/Flavivirus positive sera, respectively. Mean concentrations were
consistent across groups, around 43pg/mL, except where the convalescent DENV positive subset
produced a lower mean of 22.47pg/mL. Standard deviations were ~18pg/mL for most groups, with the
DENV negative sera subset standard deviation (σ=63.54pg/mL) exceeding its mean (μ=42.06pg/mL),
while the acute DENV positive group standard deviation nearly matched its mean (μ=43.05pg/mL,
σ=35.65pg/mL).
IP-10 analyte data contained nearly all detectable concentrations, with the greatest sample group
interquartile range observed in the acute DENV positive group of 8971.42pg/mL. Six sera (~43%) from
this set had concentrations above detectable limits, which was not observed for any other subset or
analyte. These values were replaced with 9000pg/mL, in order to facilitate calculations. The interquartile
range of the DENV negative subset was 4126.63pg/mL, while the remaining groups had interquartile
ranges below 1500pg/mL. However, DENV negative sera had the highest median IP-10 concentration of
2216.60pg/mL, followed by acute DENV positive sera (median=1336.21pg/mL). Medians under
975pg/mL were found for the other sets of sera. Each group mean and standard deviation were
comparable within each subset, i.e. DENV negative (μ=2279.55pg/mL, σ=3107.59pg/mL), but not across
groups, except for convalescent DENV positive and DENV negative sera.
Values for the MCP-1 analyte were similar to those observed for IFN-γ. All concentrations were
below 250pg/mL and only one undetectable value was obtained. The smallest interquartile range was
36.56pg/mL (convalescent WNV/Flavi positive) and was analogous to those calculated for the other sera
subsets, which were in the forties. Means (~47pg/ml) and standard deviations (~57pg/mL) were similar
within and across sera subsets. Medians were comparable across sample groups, ranging from
16.28pg/mL to 36.59pg/mL.
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Differences between sera sample subsets tested by 27-plex MIA were not statistically significant
for any of these analytes by ANOVA, additionally GM-CSF analyte concentrations were undetectable.
Despite the absence of statistical significance in the differential detection of these 4 analytes and GMCSF, all 5 candidate analytes were included in the subsequent experiment detailed below. This was due
in part, to their expression compared to that of the other 22 analytes among the sera samples here, our
group’s unpublished in vitro data as mentioned above, and finally due to their presumed importance in the
pathogenesis of dengue[7-9,12,13,16-18].

3.3.2. Detection and Quantification of Select Cytokines and Chemokines of Selected Serum
Samples via 5-plex MIA

A subsequent group of 24 serum samples fitting one of four criteria (see Methods 3.5.4.1.) were
chosen for MIA analysis in a custom 5-plex assay; these analytes were chosen, in part, due to the results
of the previous set, in addition to unpublished data as mentioned above. The goal of using serum
samples here was to determine if the detection levels of the 5 chosen analytes resulted in observed
profiles of differential detection for each of the cytokines/chemokines among the included subsets of sera
as detailed in Methods. Each analyte chosen for inclusion in the 5-plex assay produced observable
detection levels (Figs. 3.2-3.6) within at least two of the four sample subsets. Results here were also
compared to the detection levels of these analytes via MIA in a separate study using healthy individuals
(shaded area of Figs. 3.2a-6a)[21]. The inclusion of DENV qRT-PCR positive samples in this assay
proved to support the selection of these 5 analytes when compared to DENV ELISA positive/PCR
negative samples and negative sera (with the exception of GM-CSF) as well as healthy subjects.
In all, 4 of the 5 analytes (IL-10, IFN-γ, IP-10, and MCP-1) discussed here were detected in all 5
sera groups of the first set of samples, as well as all 4 of the groups of sera in the second set of samples.
GM-CSF, which was not detected in any of the sera (below the limit of detection) in the initial group of
sera was only detected in two groups of samples in this second set, the first being the DENV qRT-PCR+
samples. DENV negative samples obtained from a serosurvey that were included due to their
presumably healthy status, were also found to have GM-CSF present. Perhaps most importantly, each of
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the 5 analytes were detected in markedly higher average concentrations in DENV qRT-PCR+ samples as
opposed to samples that were only serologically positive for anti-DENV IgG (Table 3.2), including GMCSF. Detection of viral RNA in patients indicates current infection and therefore presumably acutely ill
patients, an important indicator for differentiating immunological profiles between groups of patients.
Concentrations of each analyte were approximately ten times higher (or more) on average for
DENV PCR+ sera than any other category with few exceptions (Table 3.2). GM-CSF was on average
found in higher concentrations for DENV negative patients from the serosurvey than those from DENV
PCR+ patients. IFN-γ was found only 2-5 times higher on average in PCR+ sera than all but two other
categories (DENV ELISA+ convalescent sera and clinical negative sera). Clinical negative sera were
also found to be only approximately 2 times lower on average for IP-10 and 3 times lower for MCP-1 than
DENV PCR+ sera. The final exception was that MCP-1 was found to be produced on average 2.5 times
higher in DENV+ PCR sera than samples positive for DENV IgG only.
It must be noted, however, that the range of values obtained for the largest group (PCR positive
sera) does skew these average concentration value comparisons in some instances. For instance, while
GM-CSF was found, on average, in higher concentrations for DENV negative sera from the serosurvey
(n=3), the highest actual value obtained from these samples was 21.41pg/mL, whereas the highest value
obtained from the DENV PCR positive samples (n=14) was 96.7pg/mL (Table 3.2). Possible reasons for
this discrepancy in GM-CSF detection are discussed below. Samples that were found to be above the
range of detection were an issue, particularly for IP-10 in acute DENV positive ELISA sera (1st set) and
MCP-1 (2nd set) where n=6 and n=1 sample(s), respectively, were out of range and so the reported
average concentrations here are artificially skewed lower. Additionally, markedly higher concentrations of
IFN-γ were produced in only 2 of 14 DENV qRT-PCR+ samples yet the average of these values still lies
above the range for that of presumably healthy individuals in Kleiner et al[21]. where subjects were ruled
out if reporting any acute or chronic condition or were on medication.
While the above problems involved with this study are factual, nonetheless this study has
established the framework of an immunological profile for uncomplicated dengue compared to healthy
individuals using these five markers as none of the analytes on average fall within the range of average
production by a healthy individual. Concentrations of IL-10, IFN-γ, IP-10, and MCP-1 were found to be
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higher, on average, in DENV PCR+ patients than healthy individuals, while the concentration of GM-CSF
was found to be lower on average in the former than the latter. Furthermore, while the variance in
concentrations remains for 4 of the 5 analytes (excluding GM-CSF) between any given individual, it is
also important to note that most of these observed concentrations are above the range produced by
healthy individuals.
Figures (3.2-3.6) illustrate the concentrations (pg/mL) of five analytes (IL-10, IP-10, MCP-1, IFNγ, and GM-CSF) as determined by 5-plex MIA. The shaded area in each figure represents the range of
concentrations obtained for each analyte when also measured by MIA in healthy individuals within a
separate study (Figs. 3.2a-3.6a)[21]. Two sets of sera were compared; DENV positive and DENV
negative. While diagnostic status was determined by both qRT-PCR and ELISA, the DENV positive
group included only samples detected by PCR for analysis.
Although statistically significant p-values were not obtained with 27-plex MIA screening, results
of the 5-plex MIA analysis (Fig. 3.2-3.6) suggest that significant differences in the concentrations of at
least 3 of the 5 analytes may occur in acutely DENV positive sera. Comparison of IL-10 concentrations in
positive versus negative sera (Fig. 3.2a-b), evidenced a statistically significant elevation of the IL-10
analyte [p=0.035, t(17)=1.94] in DENV+ specimens. Borderline p-values were calculated for
concentrations of IP-10 [p=0.093, t(17)=1.38] (Fig. 3.3a-b) and MCP-1 [p=0.058, t(15)=1.67] (Fig. 3.4a-b)
when comparing DENV positive and negative samples.
The p-values illustrating differences in IFN-γ [p=0.193, t(17)=0.89] (Fig. 3.5a-b) and GM-CSF
[p=0.493, t(17)=0.02] (Fig. 3.6a-b) analyte concentrations by 5-plex MIA did not suggest statistically
significant differences between diagnostic groups. This implies that although the presence of these
analytes may be detected by MIA, similar concentrations might be found in DENV positive specimens as
would be identified in DENV negative samples. However, a range of expected concentrations cannot be
determined with data from this study, due to the small sample size of sera, particularly in DENV negative
sera tested (n=5). It is important to note that small sample sizes may also affect the reproducibility of
these results, for both negligible and borderline (p>0.05) as well as statistically significant (p<0.05)
differences.
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3.3.3. Developing Immunological Profiles for DENV-infected Individuals

While it may be interesting, or even useful, to compare detection of a specific analyte among two
or three groups of sample types, it must be remembered that the most important long-term goal of the
study is to develop a cytokine/chemokine profile for DENV infections that would guide development of the
MIA for prognostic purposes. It may at first glance be surprising that IP-10 was detected at the highest
concentrations for DENV qRT-PCR+ and DENV negative clinical samples (2 nd sample set), but it is likely
that the latter group were patients who were experiencing some kind of illness as opposed to samples
from the serosurvey, given the clinical origin of the samples. On the other hand, GM-CSF was only
detected in DENV qRT-PCR+ samples and DENV negative samples from the serosurvey, but it is not
known what other characteristics of these individuals in the survey were present at time of collection
outside of specific selection criteria. While the average response of each analyte was detected in a
markedly higher fashion for DENV qRT-PCR+ samples, again, this does not serve to inform prognosis,
even retroactively, as all patients resulted in uncomplicated illness. Rather, the important aspect to
consider here is that these results point towards immunological profiles distinguishing acutely ill patients
with uncomplicated dengue from convalescent patients and healthy individuals. While these results may
in fact illustrate immunological profiles that prove beneficial to resolution of disease, unfortunately, the
lack of available clinical serum samples from patients that developed severe DENV illness abrogates any
information that would be useful for determining prognoses. The true test, and thus the true utility of the
assay, will be to analyze a set of analytes (cytokines/chemokines) that are differentially expressed, at the
time of clinical presentation, from those patients that will exhibit less severe manifestations of DENV
illness from those that will experience severe illness. Hopefully, some or all of these markers can lead to
that particular need; this will be investigated further in future studies.
Profiling disease outcome or novel intervention in DENV infections has been en vogue recently,
including those determined by similar MIAs. In vitro immune responses were measured where potential
therapeutics such as dexamethasone[14] and vitamin D3[17] were shown to downregulate the inflammatory
response in dengue infected cell lines, including decreased levels of IL-10, where the former study was
performed by MIA. The temporal profile of VEGF production in the HPMEC ST1.6R cell-line as
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determined by MIA in a study by Azizan et al[10]. further illustrates the utility of the platform and this
approach in selecting markers detected at differential levels at a suitable time during clinical presentation
of dengue patients. Another study showed that both IP-10 (at two distinct levels) and MCP-1 were found
to be elevated in dengue patients via MIA versus controls; this group also considered the presence or
absence of both fever and arthralgia as co-variables[13]. In NI Reis et al[17]. IL-10 was detected at
significantly higher concentrations in DENV infected monocytes than controls (which remained near
undetectable levels). However, as these concentrations were obtained via infection of a single cell-type
in an in vitro model, the specific values obtained cannot be directly compared to values obtained in our
study. A study by Appanna et al[12]. showed via MIA that IFN-γ is downregulated in uncomplicated
dengue and upregulated in severe dengue when compared to healthy individuals. Healthy controls
exhibited a mean serum concentration of 157.2pg/mL, those exhibiting uncomplicated dengue had a peak
average of 89.8pg/mL at days 4-6 of illness, and severe dengue patients showed a peak mean of
192pg/mL at days 2-3 post-onset (and the lowest mean here was 184.8pg/mL at days 7 or above during
illness). The mean concentration of 241.08pg/mL obtained for DENV PCR+ for IFN-γ in our study
exceeded all of the mean concentrations obtained in the aforementioned study. This group also showed
that the temporal profile of IP-10 production is highest in acute cases of both mild and severe dengue and
wanes over time, where production is much higher in both when compared to healthy controls (but is
highest in severe cases). Healthy controls exhibited a mean concentration of 1114.7pg/mL,
uncomplicated dengue patients had detectable average levels of IP-10 ranging from 46,967-20,505pg/mL
in a waning fashion during course of illness. For DENV PCR+ individuals in our study, the mean
concentration of IP-10 was 19115pg/mL, far from the peak of DENV+ patients in the aforementioned
study, but also far from their healthy individuals. Likewise, severe dengue patients showed a similar but
more magnified profile where the range of peak means of 71569pg/mL in those at days 2-3 of illness
decreased to 24852pg/mL. MCP-1 production showed a similar profile but where differences between
non-severe and severe dengue were marginal. Healthy controls evidenced mean MCP-1 concentrations
of 84.1pg/mL, while the profiles of both uncomplicated dengue (397.6-117.1pg/mL) and severe dengue
patients (400.4-152.3pg/mL) showed a similar pattern of decreasing detection from days 2-3 to 7 and
beyond onset of illness. In our study, the mean concentration of MCP-1 production in DENV PCR+
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individuals was 506pg/mL and, like IL-10, exceeds all average detectable levels for MCP-1 production in
the study mentioned. The factor for these differences between studies may be due to population
differences (i.e. those in endemic areas versus travel-associated cases). Finally, in a study by Yeo et
al[22]. a large number of host markers, including TNF-α and IL-10, were found to be downregulated in
asymptomatic, dengue-infected individuals along with upregulation of a few markers such as RANTES,
evidencing further the diverse profiles possibly produced during the course of infection. Although this
study used gene regulation as the determining factor, MIA may have easily been substituted in its place
for measuring concentrations of these markers instead. Taken together, these studies as well as the one
reported here, further support the utility of the MIA in developing immunological profiles for DENV
infections.
Furthermore, while the aims of this study did not explicitly include developing a more complete
model of DENV pathogenesis, mechanistically speaking, some additional observations of these results
are worth mentioning due to the specifics of certain profiles of markers that were obtained. For instance,
upregulation of IFN-γ, shown elsewhere to be at highest concentrations during the febrile phase, induces
production of IP-10 (CXCL10). In turn, the in vivo polymeric form of IP-10 and its cognate receptor
CXCR3 have been shown to be important for leukocyte/T-cell migration from the endothelium to sites of
inflammation in the tissue[23]. IL-10 has been shown to be elevated in production all the way through to
defervescence and its elevation is even higher in severe illness [24]. The literature modeling the
pathogenesis of DENV therefore supports both the inclusion of these analytes in addition to the profiles
observed in acute sera (DENV PCR+) in this study. It will be interesting to determine the biological
relevance of the markers chosen here in further establishing a more complete model of DENV
pathogenesis. These results therefore, provide the groundwork for future studies with the hope of
providing some sort of contribution in understanding the complex biological mechanisms involved in the
various manifestations of this disease.
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3.4. Conclusions

In conclusion, the detection of differential levels of all 5 cytokines and chemokines (GM-CSF, IL10, IFN-γ, IP-10, and MCP-1) via MIA seems to point to clear differences in the immunological profiles
between acutely infected and those of convalescent DENV positive patients as well as DENV negative
individuals. These differences are even more pronounced when compared to healthy individuals.
Furthermore, statistical analyses support or at least point towards significant differences for at least 3 of
the 5 analytes (IL-10, IP-10, MCP-1) included in the 5-plex assay when comparing all DENV+ samples
versus all negative sera. Thus, we conclude that at least 3 of the 5 analytes chosen show promise for
determining useful immunological profiles specific to dengue. Repeating this study with a larger sample
size would likely strengthen p-values, providing more compelling evidence that the concentrations of IL10 detected via MIA are higher in sera testing DENV+ by PCR and/or ELISA and/or return converse
conclusions about MCP-1 and IP-10 analytes. Similarly, increasing sample size may also produce more
statistically significant observed profiles for GM-CSF and IFN-γ. Additionally, quantification of expected
normal and abnormal ranges of the five analytes in DENV positive and negative samples may also be
possible with more sera subset testing. Future goals include the confirmation of study findings utilizing
greater sample numbers, the inclusion of acute sera obtained from severe dengue infections, selecting
appropriate analytes to differentiate non-severe from severe cases of DENV prior to progression, and
selecting an appropriate number of analytes for assay feasibility.

3.5. Methods

3.5.1. Ethics Statement

The removal of identifiers and blinding of previously collected diagnostic samples resulted in this
study being determined as not meeting the definition of human research activities and thus IRB exempt
under US 45 CFR 46.101(4). This ruling was determined by the University of South Florida IRB.
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3.5.2. Dengue Diagnostic Status of Samples Selected for Study

The first set of serum samples selected for inclusion in the 27-plex MIA (n=38) were previously
assayed at the Bureau of Public Health Laboratories (BPHL)-Tampa for the presence of arboviral
antibodies by IgG and IgM-MAC ELISA, including DENV, WNV, and SLEV, via protocols adapted from
CDC (Ft. Collins, CO). The second set of sera, regardless of source (see below), were previously
assayed for DENV infection by any combination of 3 assays. Each sample may have had diagnostic
status for DENV established by any combination of a CDC approved DENV TaqMan-based qRT-PCR
(San Juan, PR) and/or the previously mentioned ELISAs.

3.5.3. Detection and Quantification of Select Cytokines and Chemokines Produced in vivo (DENV
Positive Patient Sera) via 27-plex MIA

3.5.3.1. Sample Selection

A series of 38 de-identified serum samples provided by BPHL-Tampa were selected based on
specific clinical and serological criteria and subsequently blinded and randomized prior to use in this
study. Acute DENV positive sera (S1) would indicate either detection of anti-DENV IgM in a sample or
that of a four-fold increase in anti-DENV IgG titers from acute sera (S1) to convalescent sera (S2). BPHLTampa may also serologically detect either WNV or SLEV antibodies in patient sera but due to crossreactivity within the assay the etiological agents are not always clearly identified. These samples are
termed here as either non-DENV flavivirus (FLAVI) positive or negative. Past flaviviral infections included
samples where IgG titers were not indicative of a recent infection. The following criteria were used for
selection and based on ELISA results: 1. acute positive sera (S1) for dengue (DENV+, n=14), nondengue flavivirus (FLAVI+, n=4) 2. convalescent positive sera (S2) for DENV+ (n=7) 3. convalescent
(S2, S3) or past flavivirus positive of indeterminate onset (FLAVI+, n=4) 4. arbovirus negative (n=4).
One DENV+ sample from each of the S1 and S2 subsets were positive via RT-PCR.
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3.5.3.2. Cytokine and Chemokine Analysis of Selected Patient Sera via 27-plex MIA

Thirty-seven samples of sera were ran in duplicate wells and concentrations determined via
BioPlex Manager 5.0 software (Bio-Rad, Hercules, CA). Concentrations were reported as the average of
the resultant two values when compared to standard curves generated against known values of the
analytes that were provided for in the kit. The analytes included in the Bio-Plex Pro Human Cytokine 27plex Assay (Bio-Rad #M500KCAF0Y) for MIA are listed in Table 3.1. All other steps were followed per
manufacturer’s instructions[20].

3.5.3.3. Statistical Analysis of Results Obtained for Selected Patient Sera Measured via 27-plex MIA

One-way, Between Groups ANOVA in Microsoft Excel 2013 was performed to compare sera
subset analyte concentrations by 27-plex MIA. The same software was used to generate boxplots of
concentrations for sample subsets, which were created to illustrate variability, range, and central value
across sera subsets.

3.5.4. Detection and Quantification of Select Cytokines and Chemokines of Selected Serum
Samples via 5-plex MIA

3.5.4.1. Sample Selection

A series of 24 de-identified serum samples provided by the BPHL-Tampa Lab were obtained
either from the clinical archive or by way of a serosurvey conducted in Martin County during the course of
a DENV outbreak in 2013. The sera were selected based on specific molecular and serological criteria
and subsequently blinded and randomized prior to use in this study. Sera that were positive via qRTPCR for DENV indicate sera that contained DENV viral RNA and therefore an active or very recently
active infection. Sera that were DENV positive for IgG only indicate samples that were found to have
detectable anti-DENV IgG but not DENV RNA or anti-DENV IgM. These may include samples from
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actively infected secondary infections, convalescent patients, or those that may have been infected in the
past. The DENV negative samples here fall under one of two criteria, in both cases the samples were
negative for DENV but came from either the BPHL-Tampa clinical sample archive or from a serosurvey
conducted in Martin County during a DENV outbreak. The following criteria were used for selection and
based on either PCR or ELISA results, or both: 1. TaqMan-based qRT-PCR DENV+ (n=14) 2. DENV+,
IgG only (n=4) 3. DENV negative (BPHL-Tampa clinical archive, n=2) 4. DENV negative (Martin County
serosurvey, n=4).

3.5.4.2. Cytokine and Chemokine Analysis of Selected Serum Samples via 5-plex MIA

Twenty-four samples of sera were ran in duplicate wells and analyte concentrations as
determined via BioPlex Manager 5.0 software were reported as the average of the resultant two values.
These concentrations were extrapolated from standard curves generated against known values of the
analytes. The 5 analytes included in this 5-plex custom MIA are listed in bold in Table 3.1 and included
the bead sets for detecting: IL-10 (Bio-Rad #171-B5010M), GM-CSF (Bio-Rad #171-B5018M), IFN-γ (BioRad #171-B5019M), IP-10 (Bio-Rad #171-B5020M), and MCP-1 (Bio-Rad #171-B5021M). The 5-plex
MIA was performed per manufacturer’s instructions[20]. Reagents included in the 27-plex assay kit not
included with the 5-plex custom MIA kit were provided via the Bio-Plex Pro Human group I Cytokine
standards (Bio-Rad #171-D50001) and the BioPlex Pro™ reagent kit (Bio-Rad #171-304070). The latter
included antibody diluent, standard diluent, sample diluent, assay and wash buffers, streptavidin-PE, 1 x
96 well filter plate, and plate sealing tape.

3.5.4.3. Statistical Analysis of Results Obtained for Selected Patient Sera Measured via 5-plex MIA

The Two-Sample, t-Test Assuming Unequal Variances was used to statistically assess
differences between DENV positive and negative sera subsets in the 5-plex assay. Microsoft Excel 2013
was used to perform the analysis and create graphical displays of the data. Due to the limited availability
of suitable specimens, analyte concentrations in biologically similar subsets (DENV negative sera) were
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aggregated during analysis to strengthen the reliability and reproducibility of the analysis; i.e. DENV
negative (DOH) n=2 and DENV negative (serosurvey) n=3 were analyzed as one group (n=5). DENV+
sera by PCR were incorporated into the analysis, while sera found to be DENV positive by IgG were
excluded. The two-fold rationale behind this omission can be attributed to the inadequate sample size of
the IgG DENV+ group (n=2) and the increased likelihood of a familywise error occurring as more
comparison groups are included in an analysis.

3.6. Availability of Supporting Data

The datasets supporting the conclusions of this article are available in the Open Science
Framework (OSF) repository at https://osf.io with the persistent, external
identifiers doi:10.17605/OSF.IO/SRB6Dand ark:c7605/osf.io/srb6d.
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Table 3.1: Cytokine and chemokine target analytes of commercially available 27-plex MIA.
Analytes in bold denote those chosen for subsequent 5-plex custom MIA.
27-plex MIA cytokine kit (target analytes):
IL-1β
IL-8
IL-1ra
IL-9
IL-2
IL-10
IL-4
IL-12(p70)
IL-5
IL-13
IL-6
IL-15
IL-7
IL-17

Eotaxin
Basic FGF
G-CSF
GM-CSF
IFN-γ
IP-10
MCP-1

MIP-1α
MIP-1β
PDGF-BB
RANTES
TNF-α
VEGF
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Table 3.2: Average concentrations (pg/mL) of the 5 analytes chosen for inclusion in 5-plex MIA in two different sets of serum samples.
The table below lists the average observed concentrations (pg/mL) of each of the five chosen analytes for inclusion in a multiplexed DENV MIA
(IL-10, GM-CSF, IFN-γ, IP-10, and MCP-1) for the two sample sets included for study. The first sample set (top) included diagnostics via serology
only, with samples obtained from the BPHL-Tampa archive. The second sample set included both molecular and serological diagnostic methods
from BPHL-Tampa archived samples in addition to samples obtained from a serosurvey in an outbreak setting (Martin County, FL). Note that the
inclusion of DENV qRT-PCR+ samples led to much higher detection of concentrations of all five analytes via MIA. Here, listed values are average
concentrations of each sample group rather than individual samples Range of values are included parenthetically, 0 values represent those below
limits of detection. (* denotes values in range that were above detection limits, n=5 for [IP-10] S1 DENV+, n=1 for [MCP-1] DENV PCR+, <LODbelow limit of detection).
Average [target analyte] pg/mL
Sample subset

[IL-10]

[GM-CSF]

[IFN-γ]

[IP-10]

[MCP-1]

S1 DENV+

7.53(0-40.3)

<LOD

43.05(0-115.09)

469.18(0-1095.27*)

48.49(0-231.82)

S1 FLAVI+

0.04(0-0.15)

<LOD

43.51(30.25-66.05)

395.44(309.7-463.63)

57.80(24.98-143.37)

S2 DENV+

0.97(0-6.43)

<LOD

22.47(2.38-47.46)

2039.08(327.61-8679.03)

48.86(15.87-94.88)

S2 FLAVI+

0.01(0-0.04)

<LOD

44.26(24.96-66.5)

1168.93(252.57-2532.72)

35.21(11.97-58.29)

Neg (DOH)

0.09(0-0.18)

<LOD

42.06(0-136.38)

2779.55(0-6685.01)

47.58(5.01-152.75)

DENV PCR+

86.75(1.28-330.17)

7.12(0-96.7)

241.08(0-1879.6)

19114.99(40.81-56756.27)

505.91(43.12-1500.98*)

DENV+ IgG only

2.10(1.16-3.04)

0.00

90.82(0-181.64)

6818.85(1757.9-11879.79)

189.11(63.13-315.09)

DENV neg (DOH)

4.65(0.32-8.97)

0.00

12.82(0-25.64)

13995.25(1158.47-26832.03)

165.30(93.02-237.58)

DENV neg
(serosurvey)

0.47(0-0.76)

11.52(0-21.41)

52.41(0-95.61)

769.62(475.98-1176.56)

67.77(42.06-84.86)
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Fig. 3.1a-1d: Production of IL-10, IFN-γ, IP-10, and MCP-1 in serum samples as determined by 27plex MIA as illustrated by box-plot. Figures 1a-1d contain boxplots comparing DENV positive (acute
and convalescent), WNV/Flavivirus positive (acute and convalescent) and DENV negative sera analyte
concentrations as determined via 27-plex MIA. Four analytes are shown: IL-10, IFN-γ, IP-10 and MCP-1.
Upper and lower bars represent the maximum and minimum concentration values obtained for each
analyte within each subgroup, respectively. Top and bottom portions of the boxes mark the second and
third quartiles and together represent the interquartile range (IQR). Lines within the boxes represent
median concentration values. One-way ANOVA was used to assess differences between groups, with
results shown at the top of each figure. A fifth analyte, GM-CSF is not shown in this series of figures as
corresponding assay values were below the limits of detection for all sera sample subsets. Note that no
statistically significant differences were observed between groups for any of the above 4 analytes.
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Fig. 3.2a-2b: IL-10 production (pg/mL) in serum samples as determined by 5-plex MIA. Figure 2a
illustrates the observed average concentrations (pg/mL) of IL-10 in individual specimens as determined
by MIA for DENV PCR+ and DENV- samples. Figure 2b shows boxplots of IL-10 concentrations (pg/mL),
by DENV diagnostic group [DENV+, (n=14) and DENV- (n=5)]. Upper and lower bars represent the
maximum and minimum concentration values obtained for IL-10 within each subgroup, respectively. Top
and bottom portions of the boxes mark the second and third quartiles and together represent the
interquartile range (IQR). Results of t-tests are also shown in Fig. 2b Here, the IQR of DENV PCR+
samples lies entirely above that of DENV- samples, and the difference between groups was statistically
significant (p=0.035). Furthermore, 8 of the 14 concentration values of DENV PCR+ sera were markedly
higher than those in the DENV negative group. Note that the shaded area represents the range of
concentrations obtained for each analyte when also measured by MIA in healthy individuals within a
separate study where most values obtained from DENV PCR+ sera were found to significantly exceed
this range and all DENV- values were found to be below this range[21].
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Fig. 3.3a-3b: IP-10 production (pg/mL) in serum samples as determined by 5-plex MIA.
Figure 3a illustrates the observed average concentrations (pg/mL) of IP-10 in individual specimens as
determined by MIA for DENV PCR+ and DENV- samples. Figure 3b contains boxplots detailing IP-10
concentrations (pg/mL) by DENV diagnostic group [DENV+, (n=14) and DENV- (n=5)]. Upper and lower
bars represent the maximum and minimum concentration values obtained for IP-10 within each subgroup,
respectively. Results of t-tests are also shown in Fig. 3b. While statistically significant differences
between groups were found to be borderline (p=0.093), note that the IQR of DENV PCR+ samples lies
entirely above that of DENV- samples. Additionally, the maximum concentration values between groups
was nearly two-fold higher for DENV PCR+ sera (56756.27pg/mL compared to 26832.03pg/mL). Note
that the shaded area represents the range of concentrations obtained for each analyte when also
measured by MIA in healthy individuals within a separate study[21].

75

Fig. 3.4a-4b: MCP-1 production (pg/mL) in serum samples as determined by 5-plex MIA.
Figure 4a illustrates the observed average concentrations (pg/mL) of MCP-1 in individual specimens as
determined by MIA for DENV PCR+ and DENV- samples. Figure 4b contains boxplots detailing MCP-1
concentrations (pg/mL) by DENV diagnostic group [DENV+, (n=13) and DENV- (n=5)]. Results of t-tests
are also shown in Fig. 4b. While statistical differences between groups were found to be borderline
(p=0.058) being slightly above the test threshold of p=0.05, observe that the IQR of DENV PCR+ samples
lies entirely above that of DENV- samples. Also, the maximum concentration values between groups was
much higher in the DENV+ group than that of DENV- samples (1500.98pg/mL compared to
237.58pg/mL). This also does not include a DENV PCR+ sample that was not included in analysis due to
the fact that its value was beyond that of the detection limits of the assay. Note that the shaded area
represents the range of concentrations obtained for each analyte when also measured by MIA in healthy
individuals within a separate study[21].
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Fig. 3.5a-5b: IFN-γ production (pg/mL) in serum samples as determined by 5-plex MIA.
Figure 5a illustrates the observed average concentrations (pg/mL) of IFN-γ in individual specimens as
determined by MIA for DENV PCR+ and DENV- samples. Figure 5b contains boxplots detailing IFN-γ
concentrations (pg/mL) by DENV diagnostic group [DENV+, (n=14) and DENV- (n=5)]. Upper and lower
bars represent the maximum and minimum concentration values obtained for IFN-γ within each subgroup,
respectively. Top and bottom portions of the boxes mark the second and third quartiles and together
represent the interquartile range (IQR). Results of t-tests are also shown in Fig. 5b. While statistically
significant differences were not found between groups (p=0.193), and the IQRs appear similar, please
observe that 5 of the 14 DENV PCR+ samples detected IFN-γ concentrations at least as twice a high or
higher than the maximum concentration value of DENV- samples (95.61pg/mL) including one dramatically
higher (1879.6pg/mL). Note that the shaded area represents the range of concentrations obtained for
each analyte when also measured by MIA in healthy individuals within a separate study[21].
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Fig. 3.6a-6b: GM-CSF production (pg/mL) in serum samples as determined by 5-plex MIA. Figure 6a
illustrates the observed average concentrations (pg/mL) of GM-CSF in individual specimens as
determined by MIA for DENV PCR+ and DENV- samples. Figure 6b contains boxplots detailing GM-CSF
concentrations (pg/mL) by DENV diagnostic group [DENV+, (n=14) and DENV- (n=5)]. Upper and lower
bars represent the maximum and minimum concentration values obtained for GM-CSF within each
subgroup, respectively. Top and bottom portions of the boxes mark the second and third quartiles and
together represent the interquartile range (IQR). Results of t-tests are also shown in Fig. 6b. Statistically
significant differences were not observed between groups (p=0.493). Also, observe the maximum
concentration value in the DENV PCR+ group (96.7pg/mL) which may represent a potential but significant
outlier. Note that the shaded area represents the range of concentrations obtained for each analyte when
also measured by MIA in healthy individuals within a separate study and that all values obtained here fell
within or below this range[21] .
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4.1. Abstract

Background: The proper management of patients infected with dengue virus requires early detection.
Here, real-time molecular assays have proven useful but have limitations, whereas ELISAs that detect
antibodies are still favored but results obtained too late to be of clinical value. The production of DENV
NS1 peaks early during infection and its detection can combine the advantages of both diagnostic
approaches.

Methods: This study compared assays currently used for detecting DENV infection at the Florida
Department of Health including anti-DENV IgM and IgG ELISAs as well as qRT-PCR, against a
commercially available DENV NS1 ELISA. These comparisons were made among a group of 21 human
sera.

Results: Nine of 14 (64.3%) DENV qRT-PCR+ samples were also DENV NS1+. Interestingly, the 5 NS1samples that were qRT-PCR+ were additionally IgM- and IgG+ suggesting a non-primary infection.
Compared to qRT-PCR, the NS1 assay had a sensitivity of 64.3% and specificity of 100%.

Conclusions: The NS1 ELISA performed as expected in known DENV qRT-PCR+ samples, however
negative NS1 results for qRT-PCR+, IgG+ sera seemingly reduced the usefulness of the NS1 ELISA for
non-primary cases. We therefore conclude that diagnosis obtained via DENV NS1 ELISA deserves
further investigation.

Key words: dengue; DENV; NS1; ELISA; diagnostics

4.2. Introduction

Infections caused by dengue virus continue to constitute a worldwide threat to the public, both in
human and economic costs. In 2017, dengue virus remains the cause of one the most globally significant
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arthropod-borne (arbo-) viral illnesses. According to WHO, there is currently an at risk global population
of 3.9 billion where an estimated 390 million infections occur annually. Around 96 million infected
persons seek clinical attention but the majority of cases go unreported. Approximately 500,000 of clinical
patients will progress to severe illness and require hospitalization with fatalities arising in 2.5% [1,2].
Additionally, after a 75-year absence, local transmission of DENV was documented in Florida, USA.
During the time period between 2009-12, 103 autochthonous cases were documented with the majority of
those cases (27 in 2009 and 63 in 2010) associated with an outbreak of DENV serotype 1 (DEN1) in Key
West (Monroe County). However, epidemiologically unrelated, locally acquired cases were also
documented in Broward, Hillsborough, Miami-Dade, Palm Beach, Osceola, Martin, and Seminole
counties through 2012. A second outbreak of DEN1 occurred in Martin County during 2013 [3-5]. Two
introductions of dengue are thought to have occurred in Martin County, the first near Port Salerno in 2011
and the second near Jensen Beach; the latter introduction responsible for the outbreak. In 2016, a case
of DEN4 (Cone M, personal comm.) was locally-acquired in Key West[6] and dengue appeared again
locally in Miami-Dade during Zika virus outbreak investigations[7].
Dengue is caused by one of four different serotypes of small RNA viruses in the family
Flaviviridae, DENV1-4. The 5’ and 3’ ends of the DENV genome contain untranslated regions (UTRs)
and the open reading frame first encodes the three structural proteins, C, prM/M, and env, followed by 7
non-structural (NS) proteins, including the NS1 protein. The genome is translated as a single polyprotein
that is processed and modified post-translationally [8]. The NS1 protein itself is secreted from infected
cells and is found in serum at detectable levels that overlap with peak viremia (and RNA detection) in
addition to the onset of detectable antibody levels of IgM in acute primary cases and IgG in acute nonprimary cases[9]. It has been found that elevated levels of serum NS1 directly indicates increased viral
burden and further establishes the positive correlation between viremia and NS1 profiles [10,11]. NS1 is a
generally conserved protein among flaviviruses but has been found to contain both cross-reactive and
serotype-specific epitopes among dengue viruses; these are important factors when considering
development of immunoassays[12-14]. For these reasons NS1 is considered as having diagnostic value as
a viral marker of infection. The protein is found both intracellularly as well as in a soluble form (sNS1)
secreted from infected host cells but its function remains enigmatic. The immature form of NS1 is that of
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a monomer that is variably glycosylated but readily forms heat-labile homodimers usually associated with
the surface of infected cells[8,14]. From there, the major oligomeric form of sNS1 is thought to be a
hexamer of around 300kD. The hexamer consists of 3 dimeric subunits that are non-covalently bound
and are less stable than NS1 dimers[15,16].
Dengue is a problematic disease to manage at the clinical level, in large part due to late
manifestations of severe illness in some patients[17]. In the past, techniques including virus isolation and
serological assays such as ELISA and plaque-reduction neutralization assays (PRNT) typically yielded
results after clinical resolution (or development of severe illness), leading to diagnosis with no benefit to
the patient. However, the capabilities of the laboratory have advanced to the level of obtaining same day
results in acutely infected patients with the advent of rapid techniques that include molecular diagnostic
assays such as real-time qRT-PCR[9]. As alluded to above, the NS1 protein of DENV is also a useful
early viral marker of infection and an ELISA (Pan-Bio® Dengue Early ELISA #E-DEN02P) that detects it
is currently available from Inverness Medical (now Alere Inc.) among other immunoassay manufacturers.
These DENV NS1 immunoassays may represent the new paradigm for DENV diagnosis in many parts of
the world, in part, by serving to combine the pros of both traditional serological assays with those of
modern molecular assays. These include early diagnosis commensurate with the capabilities of
molecular assays coupled with decreased costs in both equipment and reagents along with reducing the
technical prowess and stringency required for performing clinical molecular assays. This study attempted
to ascertain the potential value of the DENV NS1 ELISA in diagnosing dengue in the US state of Florida.

4.3. Materials and Methods

4.3.1. Ethics Statement

The removal of identifiers in these previously collected serum samples resulted in the
determination of this study as not meeting the definition of human research activities and thus IRB
exempt under US 45 CFR 46.101(4). This ruling was determined by the University of South Florida IRB.
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4.3.2. Sample Selection

A series of 21 serum samples previously assayed at the Florida Department of Health (FLDOH)Bureau of Public Health Laboratories (BPHL)-Tampa for DENV by qRT-PCR and either, anti-DENV IgM
and IgG ELISA in concert (20/21) or IgM only (1/21), were subsequently subjected to DENV NS1
detection by ELISA. Corresponding DENV serotypes of positive samples were also obtained via qRTPCR. Eight of 14 qRT-PCR+ samples were positive for DEN1, five were DEN4+, and one was DEN2+.
No samples that were identified as DEN3+ were included in this study. Dengue qRT-PCR- samples
belonged to either of the following diagnostic categories: anti-DENV IgG+ (n=2) or samples negative for
all routine DENV diagnostic assays. The latter samples were obtained from either the clinical archive
(n=2) or from a serosurvey (n=3) conducted in Martin County, Florida during the course of an outbreak of
DEN1. The DENV IgG and IgM ELISAs were adapted from protocols provided by CDC-Arboviral
Diseases Branch (Ft. Collins, CO) and TaqMan-based DENV serotype-specific qRT-PCR was performed
using an FDA-approved protocol provided by CDC-Dengue Branch (San Juan, Puerto Rico).

4.3.3. DENV NS1 ELISA

The PanBio® dengue early ELISA (Inverness Medical, Sinnamon Park, QLD, Australia #EDEN02P) was used to determine the presence of DENV NS1 in individual serum samples. Each sample
was ran in duplicate, according to manufacturer’s instructions. The assay was performed according to
manufacturer’s instructions with the following changes specific to our study. Samples, positive controls,
and negative controls were added to wells in duplicate and calibrators were added in quadruplicate, all at
100μL. The ELISA sample plates were read at 450nm with a reference filter of 620nm. Each sample
optical density (OD) value (absorbance) was averaged between duplicate wells then divided by the cut-off
value to obtain index values. Values <0.9 were ruled as negative, between 0.9 and 1.1 as equivocal, and
values above 1.1 positive for DENV NS1 detection. The results of this assay were then compared to
those of DENV virus RNA detection via qRT-PCR as well as anti-DENV IgM and IgG ELISAs previously
performed at the FLDOH-BPHL-Tampa.
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4.4. Results

In our study, the DENV NS1 ELISA (Tables 4.1 and 4.2) found 9 of 14 sera to be positive for
DENV that were also qRT-PCR+ and 0 of 2 that were previously positive by IgG only (9/16 total DENV+
samples). Five samples that were DENV- negative in all 3 comparison assays, including 2 clinical
samples and 3 from the Martin County serosurvey, were also negative via DENV NS1 ELISA. Each of
the DENV qRT-PCR+ samples that were found to be NS1 ELISA- were also negative for IgM (5/14).
Interestingly, however, these 5 qRT-PCR+ samples were positive for IgG (and IgM-) by ELISA,
suggesting non-primary infection. Additionally, each of the 3 dengue serotypes represented in this study
were found within this subgroup (3 of 5 samples were DEN1, 1=DEN2, and 1=DEN4). On the other hand,
one sample that was NS1+ presented with the same profile (i.e. qRT-PCR+, IgM-, and IgG+). All seven
qRT-PCR- samples were also negative for DENV NS1. Please take note that the desired direct
comparison between assays was that made between those capable of early detection (NS1 ELISA vs.
qRT-PCR). Therefore, while both assays failed to detect dengue in 2 samples that were IgG+ only, the
‘true negative’ sample number of (n=7) was left to stand for calculations so as not to skew the NPV
artificially in favor of qRT-PCR. In all and when compared to the results of qRT-PCR, the NS1 assay was
found to have a sensitivity of 64.3% and specificity of 100%.

4.5. Discussion

Like the results found here, previous reports of the investigational use of commercially available
DENV NS1 immunoassays such as those in Brazil[18] and Malaysia[19] showed favorable results when
compared against standard diagnostic methods. The former group used the Platelia™ Dengue NS1 Ag
microplate EIA (Bio-Rad, Hercules, CA) and the latter the SD Bioline Dengue Duo (Standard Diagnostics,
Yongin-si, Rep. Korea). These groups obtained results with sensitivities of 95.9% and 65.41% and
specificities of 81.1% and 98.75%, respectively (whereby for the SD Bioline assay, a multiplex assay, only
NS1 was considered). In 2010, the Platelia™ assay was approved for the screening of 80,000 Puerto
Rican blood donors. At the time of FDA approval for the particular study, the test was already in use in
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approximately 40 countries around the world[20]. The USNIH notes on www.clinicaltrials.gov that the
study has been completed but official results have yet to be reported[21]. In Lima MdaR et al.[22], two of
the previously mentioned assays, the PanBio® ELISA and the Platelia™ EIA, were compared against
another immunoassay, the Dengue NS1 STRIP (Bio-Rad, Hercules, CA). The STRIP is an
immunochromatographic test similar to the previously mentioned SD Bioline Dengue Duo. While all
obtained specificities near 100%, here they found the STRIP assay to have the highest sensitivity
(89.6%), followed by the Platelia™ EIA at 83.6%, and the Pan-Bio® ELISA at 72.3%. This group also
reported that the assays were less sensitive in detecting DEN3 cases and that the Platelia™ assay
detected primary cases at a statistically significant higher percentage than non-primary cases.
It should also be noted that concerns about the sensitivity of the Platelia™ EIA arose in a study in
Aracaju, Brazil where 58 of 119 NS1 negative samples were instead found later to be DEN4+ by
confirmatory tests, and their reasoning pointed to an issue with the detection of non-primary cases [23]. As
mentioned above, this was also seemingly evident in our study where all 5 NS1 ELISA- samples known to
be qRT-PCR+ were also IgG+ in ELISA. However, a subsequent report published after obtaining the
results reported here, indicated that this drawback can be alleviated by pre-heating samples at 100°C for
5m[24]. This would indicate that the assay may require dissociation of antigen-antibody complexes and/or
preferentially detects monomeric NS1 over its dimeric form. The former seems very likely as, in nonprimary infections, NS1 bound by IgG antibodies produced during the early phases would reduce the pool
of free and detectable serum levels of this protein. On the other hand, their data suggested that with
heating, the assay is preferentially detecting NS1 monomers in both types of dengue infection[14]. It would
be important to empirically determine that the heating step reported above is producing dissociation of
antigen-antibody complexes and/or dissociation of free dimeric NS1 into constituent monomers and that
this step is essential for increasing sensitivity in both types of infection.
There also remains the concern that no single assay included in this study was alone sufficient for
diagnosis. This was evident where 2 out of 7 qRT-PCR- samples were found to be DENV+ only via IgG
detection. This in turn affected the comparison between the test under question (DENV NS1 ELISA) and
the gold-standard used here for early detection (qRT-PCR). Wang and Sekaran[19] abrogated this assayrelated issue to a large extent through the use of a ‘one-stop’ rapid test able to detect not only NS1 but
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also IgM and/or IgG. This in turn increased the sensitivity of their combined assay and identified,
concurrently, more positive individuals. This and other multifaceted approaches to DENV diagnostics
seems to be the proper direction moving forward and we encourage further investigation.
Regarding our study, we accept that larger scale studies typically include greater numbers of negative
samples when characterizing new assays. Here, though, both the limited number of reagents as well as
DENV+ samples available for study compelled us to approach the study from the opposite direction.
Additionally, as part of a larger study, these samples were also subject to analyses, such as
immunological profiling[25] and experimental DENV NS1 detection, further supporting the approach used
here. Despite the small sample size included, we nevertheless conclude that assays detecting DENV
NS1 should eventually be incorporated within the algorithms of laboratories performing dengue
diagnostics, including BPHL-Tampa. We also propose that they are investigated for further utility,
especially in conjunction with not only other potential diagnostic markers, but also those of prognostic
value, in order to better inform the clinic in identifying and properly managing patients infected with
dengue.
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Table 5.1: DENV NS1 detection in selected serum samples as determined by ELISA and in
comparison to clinical molecular (qRT-PCR) and serological (anti-DENV IgM and IgG) results. The
table below details the results of DENV NS1 detection by ELISA against qRT-PCR, IgM, and IgG DENV
assays for a group of serum samples selected for inclusion and based on the following criteria: 1denotes samples positive by qRT-PCR for DENV as determined by BPHL-Tampa 2- denotes
samples positive for DENV by IgG detection only as determined by BPHL-Tampa 3- denotes
samples that were DENV negative received by BPHL-Tampa for all DENV-specific assays 4denotes samples that were collected from Martin County serosurvey and were found to be DENV
negative by all DENV-specific assays. Index values represent the mean of duplicate values obtained
when reading samples at 450nm and taking calibrators into account. Negative samples had an index
value of less than 0.9, those between 0.9-1.1 were equivocal, and those above 1.1 were positive for NS1
detection. Results are listed as either positive (+) or negative (neg) for each ELISA. Positive qRT-PCR
results are reported either as neg. or positive by listing serotype and CT value results. Samples that were
qRT-PCR+ but NS1 neg. are highlighted within the table. Note that no single assay here was capable of
diagnosing DENV infection alone.
sample

Index
value

1-1
1-2
1-3
1-5
1-6
1-7
1-8
1-9
1-10
1-11
1-12
1-13
1-14
1-15
2-3
2-4
3-1
3-2
4-1
4-2
4-3

5.98
5.91
0.08
0.09
5.93
5.93
4.51
5.38
0.17
5.97
5.92
0.21
0.25
6.00
0.43
0.13
0.05
0.09
0.05
0.06
0.06

NS1 ELISA

qRT-PCR (CT)

+
+

DEN4 (20.40)
DEN1 (14.19)
DEN1 (33.17)
DEN1 (34.96)
DEN1 (26.06)
DEN1 (30.40)
DEN1 (22.32)
DEN1 (31.90)
DEN1 (25.53)
DEN4 (29.79)
DEN4 (20.74)
DEN4 (19.69)
DEN2 (25.13)
DEN4 (21.03)
neg
neg
neg
neg
neg
neg
neg

neg
neg

+
+
+
+
neg

+
+
neg
neg

+
neg
neg
neg
neg
neg
neg
neg

IgM ELISA

IgG ELISA

+

+

neg
neg
neg

neg

+
+
+
+

neg
neg
neg
neg

neg

+
+
+
+
+
+
+
+

+
neg
neg
neg

+
neg
neg
neg
neg
neg
neg
neg

+
+

neg
neg
neg
neg
N/A
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Table 5.2: Breakdown of DENV serological diagnostic status (any combination of DENV NS1, antiDENV IgM, and/or –IgG) versus detection of DENV RNA via qRT-PCR. The table below details first
the comparison of DENV NS1 detection via ELISA compared to results obtained for the respective
sample set via qRT-PCR (n=21), set as a gold-standard. The table details a further breakdown of these
results by including anti-DENV IgM and IgG status of the samples. Nine (9 out of 14) qRT-PCR+ samples
were also DENV NS1+ (64.3%) and all 7 samples that were negative by qRT-PCR were also found to be
negative for DENV NS1. Notably, all 5 DENV NS1- samples that were qRT-PCR+ were also anti-DENV
IgM- and IgG+, while only 1 positive NS1 sample was found to have that same profile, indicating that nonprimary infections may affect the sensitivity of the DENV NS1 ELISA. *Please note that 1 of the DENV
qRT-PCR- samples was not assayed for DENV anti-IgG.
DENV qRT-PCR results vs. ELISA
DENV ELISA results

DENV qRT-PCR+ (n=14)

DENV qRT-PCR- (n=7)

DENV NS1+

9/14 (64.3%)

0/7 (0%)

DENV NS1-

5/14 (35.7%)

7/7 (100%)

DENV NS1+, IgM+

7/14 (50%)

0/7 (0%)

DENV NS1+, IgM-

2/14 (14.3%)

0/7 (0%)

DENV NS1-, IgM+

0/14 (0%)

0/7 (0%)

DENV NS1-, IgM-

5/14 (35.7%)

7/7 (100%)

DENV NS1+, IgG+

4/14 (28.6%)

0/6* (0%)

DENV NS1+, IgG-

5/14 (35.7%)

0/6* (0%)

DENV NS1-, IgG+

5/14 (35.7%)

2/6* (33.3%)

DENV NS1-, IgG-

0/14 (0%)

4/6* (66.7%)

DENV NS1+, IgM+, IgG+

3/14 (21.4%)

0/6* (0%)

DENV NS1+, IgM-, IgG+

1/14 (7%)

0/6* (0%)

DENV NS1-, IgM+, IgG+

0/14 (0%)

0/6* (0%)

DENV NS1-, IgM-, IgG+

5/14 (35.7%)

2/6* (33.3%)

DENV NS1+, IgM+, IgG-

5/14 (35.7%)

0/6* (0%)

DENV NS1+, IgM-, IgG-

0/14 (0%)

0/6* (0%)

DENV NS1-, IgM+, IgG-

0/14 (0%)

0/6* (0%)

DENV NS1-, IgM-, IgG-

0/14 (0%)

4/6* (66.7%)
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Table 5.3: Sensitivity, specificity, positive (PPV) and negative (NPV) predictive values for PanBio
DENV NS1 ELISA when compared to detection of DENV RNA via qRT-PCR. Note that the ‘true
negative’ value of n=7 was left to stand in order to prevent skewing calculations in favor of qRT-PCR even
though both assays failed to diagnose dengue correctly in 2 IgG+ samples.
DENV qRTPCR+ (n=14)

DENV qRTPCR- (n=7)

DENV NS1
ELISA+

9

0

PPV=100%

DENV NS1
ELISA-

5

7

NPV=58.3%

Sensitivity=

Specificity=

64.3%

100%
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CHAPTER 5. CONCLUSIONS

5.1. Major Points

Due to the somewhat discrete nature of the Chapters detailed in the main body of the text, this section is
included to summarize the main conclusions and remaining needs of the study.

Point 1: The MIA shows promise for becoming a useful platform for both diagnostic and prognostic
purposes with respect to DENV infections.
Specifically: Despite mixed results, DENV NS1, IL-10, MCP-1, and IP-10 should be included in future
developments. NS1 because of its successful use in other similar assays (ELISA) and the latter 3
because of their increased detection in DENV infected individuals over those that are healthy. Other
potential analytes that should merit further investigation due to our results include: IL-6, IL-8, IFN-γ,
VEGF, and RANTES.

Point 2: The ability to multiplex at a level that other techniques cannot currently provide increases the
utility of the MIA as a singular assay.
Specifically: This can only increase the potential diagnostic value of the assay as other markers are
included, such as: IgG, IgM, IgA, and DENV RNA. We also conclude that DENV NS1 remains as a
possible and most important candidate analyte for development and inclusion in MIA.

Point 3: A suitable minimum number of host markers must be identified that provide robust results in
identifying patients that will proceed to severe DENV disease from those that will not.
Specifically: IL-10, MCP-1, and IP-10 may not prove to be adequate in order to differentiate disease
outcome especially considering the lack of known severe cases in our data sets. Here other potential
candidates again include: IL-6, IL-8, IFN-γ, VEGF, and RANTES.
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Point 4: The results of this study as well as others like it demand that larger sample sizes are collected
prior to defining differential immunological profiles.

Point 5: The MIA may also be useful for elucidating pathogenesis using in vitro models.
Specifically: Here we suggest that the cell lines used within this study and their response to DENV is
investigated using a co-culture model where u937 includes treatments of uninfected and both ADE and
non-ADE models of DENV infection prior to co-culturing with HPMEC ST1.6R. We then propose that 27plex MIA should be used to determine cellular responses, possibly in conjunction with fluorescent labeling
and confocal microscopy of co-cultures. Time points should be decreased and replicates should
dramtically increase from n=2 reported here.

5.2. Future Goals

Again, we feel that the results obtained here merit additional consideration and we fully
encourage the further development of the DENV MIA. The continuation of the project would first rely
upon the acquisition of an appropriate number and type of human sera. At a minimum, sera must be
obtained from healthy individuals and acutely DENV infected individuals. Regarding DENV virus infected
individuals, the samples may be obtained from individuals that have developed warning signs for
developing severe illness but this information must be available for analyses. The ideal samples,
however, would be obtained from patients that have yet to develop warning signs, in other words early
presentations, and come from populations that result in either uncomplicated illness or severe
manifestations. This would most appropriately highlight both the early diagnostic and potential prognostic
value of the DENV MIA. Potential collaborations with groups in Florida, Puerto Rico, and/or Malaysia can
provide these samples. Obtaining samples from multiple populations may also elucidate regional
differences in results. The next stage of development would likely consist of 3 stages. First, the
continuation of 27-plex screening of sera for the identification of markers indicitave of individual disease
outcome. Second, subjecting sera from healthy or actuely DENV-infected individuals to an MIA that
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would support the results reported here. This MIA would include markers for IL-10, IP-10, and MCP-1.
Our hypothesis is that we would expect a 2-fold elevation of IP-10 and MCP-1 concentrations in severe
forms of DENV illness over uncomplicated dengue significant (p<0.05) and therefore predicitive for
disease severity. We would also expect the converse to be true for IL-10 concentrations in these specific
populations of DENV-infected individuals. During this early range of patient presentation, we expect a 2fold elevation of IL-10 concentrations to be predicitive of uncomplicated disease resolution over those that
proceed to severe illness (p<0.05). So using our data reported here of a mean concentration of
86.75pg/mL for IL-10 in DENV+ individuals (uncomplicated illness) with a standard deviation of 96 applied
to both groups, and applying this hypothesis, we find that we would need a total sample size of at least
212, equally distributed, with an observed effect size of 0.45 and α=0.05 in a one-tailed t-test (G*Power
v3.1.9.2, Franz Faul, Universitat Kiel, Germany). The third part of future investigations would include the
completion of the DENV diagnostic component of the MIA. We believe that our failure to achieve this
goal was due to the similarities between the monoclonal antibodies used for capture and detection and
we require an appropriate antibody for detection. In this respect, we would advise to search for a
previously characterized and already available mAb, that also maps to the same region (within the major
antigenic ‘wing domain’) as our capture antibody but at a different sequence of amino acids. Once this is
achieved the multiplexed assay (from 3-plex to 4-plex) can be investigated for potential losses in
sensitivity. Completion of the first goal may allow for additional development and optimization of
prognostic ability of the DENV MIA. Completion of the second and third goals would achieve the main
goal of providing for a diagnostic assay for DENV that is also predictive according to disease severity.
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